Eltrombopag for the Treatment of Chronic Idiopathic T

New England Journal of Medicine 357, 2237-2247 DOI: 10.1056/nejmoa073275

Citation Report

#	Article	IF	CITATIONS
1	Eltrombopag for Thrombocytopenia in Patients with Cirrhosis Associated with Hepatitis C. New England Journal of Medicine, 2007, 357, 2227-2236.	27.0	420
2	Immune Thrombocytopenic Purpura — From Agony to Agonist. New England Journal of Medicine, 2007, 357, 2299-2301.	27.0	38
3	What's new in the other general journals. BMJ: British Medical Journal, 2007, 335, 1178-1179.	2.3	1
4	Severe chronic refractory immune thrombocytopenic purpura during childhood: A survey of physician management. Pediatric Blood and Cancer, 2008, 51, 513-516.	1.5	32
5	Molecular features crucial to the activity of pyrimidine benzamide-based thrombopoietin receptor agonists. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 3000-3006.	2.2	13
6	Discovery and biological evaluation of benzo[a]carbazole-based small molecule agonists of the thrombopoietin (Tpo) receptor. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 5255-5258.	2.2	24
7	Optimization of small molecule agonists of the thrombopoietin (Tpo) receptor derived from a benzo[a]carbazole hit scaffold. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 5259-5262.	2.2	14
8	Improved Granulocyte Colony-Stimulating Factor Mobilization of Hemopoietic Progenitors Using Cytokine Combinations in Primates. Stem Cells, 2008, 26, 2974-2980.	3.2	6
9	Boosting platelet production. Nature Medicine, 2008, 14, 917-918.	30.7	6
10	Romiplostim. Nature Reviews Drug Discovery, 2008, 7, 887-888.	46.4	37
11	Compromised ITAMâ€based platelet receptor function in a patient with immune thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2008, 6, 1175-1182.	3.8	56
12	Refractory immune thrombocytopenic purpura: current strategies for investigation and management. British Journal of Haematology, 2008, 143, 16-26.	2.5	72
13	Emerging treatments for thrombocytopenia: Increasing platelet production. Drug Discovery Today, 2008, 13, 798-806.	6.4	31
14	Eltrombopag, le nouveau traitement du purpura chronique idiopathique. Option/Bio, 2008, 19, 5.	0.0	0
15	New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura. European Journal of Haematology, 2008, 80, 9-18.	2.2	38
16	Emerging strategies to treat chronic immune thrombocytopenic purpura. European Journal of Haematology, 2008, 80, 27-33.	2.2	9
17	Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results. European Journal of Haematology, 2008, 81, 165-169.	2.2	65
18	Novel Thrombopoietic Agents. Drugs, 2008, 68, 901-912.	10.9	64

ARTICLE IF CITATIONS # Overview of Thrombopoietic Agents in the Treatment of Thrombocytopenia. Clinical Lymphoma and 19 1.4 8 Myeloma, 2008, 8, 33-43. Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opinion on Emerging 2.4 Drugs, 2008, 13, 237-254. Eltrombopag for the treatment of idiopathic thrombocytopenic purpura. Expert Review of 21 2.2 5 Hematology, 2008, 1, 145-152. The gut–liver-axis: Endotoxemia, inflammation, insulin resistance and NASH. Journal of Hepatology, 2008, 48, 1032-1034. Eltrombopag: An effective remedy for thrombocytopaenia?. Journal of Hepatology, 2008, 48, 1030-1032. 24 3.7 1 Thrombocytopenia associated with chronic liver disease. Journal of Hepatology, 2008, 48, 1000-1007. 3.7 Finding a place for thrombopoietin receptor agonists in the treatment of chronic ITP. Community 0.2 26 1 Oncology, 2008, 5, 653-654. Romiplostim: the risk evaluation and mitigation strategy (REMS). Community Oncology, 2008, 5, 654-655. 0.2 28 Increasing the platelet count in chronic ITP. Lancet, The, 2008, 371, 362-364. 13.7 4 Childhood Immune Thrombocytopenic Purpura: Diagnosis and Management. Pediatric Clinics of North 1.8 America, 2008, 55, 393-420. The Pathophysiology of ITP Revisited: Ineffective Thrombopoiesis and the Emerging Role of Thrombopoiétin Receptor Agonists in the Management of Chronic Immune Thrombocytopenic Purpura. 30 23 2.5 Hematology American Society of Hematology Education Program, 2008, 2008, 219-226. Eltrombopag in Thrombocytopenia. New England Journal of Medicine, 2008, 358, 1072-1073. How effective is eltrombopag for the treatment of thrombocytopenia in patients with HCV infection?. 32 1.7 3 Nature Reviews Gastroenterology & Hepatology, 2008, 5, 424-425. Novel thrombopoietic agents: a new era for management of patients with thrombocytopenia. Haematologica, 2008, 93, 1445-1449. 3.5 A possible role for low-dose cyclosporine in refractory immune thrombocytopenic purpura. 35 3.5 15 Haematologica, 2008, 93, 1113-1115. Haematopoietic growth factors and their therapeutic use. Thrombosis and Haemostasis, 2008, 99, 863-873. From Hematopoietic Stem Cells to Megakaryocytes and Platelets., 2008, 162-177. 37 1 The use of second-generation thrombopoietic agents for chemotherapy-induced thrombocytopenia. 2.4 Current Opinion in Oncology, 2008, 20, 690-696.

#	Article	IF	Citations
40	Treatment of immune thrombocytopenic purpura: focus on eltrombopag. Biologics: Targets and Therapy, 2009, , 151.	3.2	5
41	New advances in the treatment of adult chronic immune thrombocytopenic purpura: role of thrombopoietin receptor-stimulating agents. Biologics: Targets and Therapy, 0, , 499.	3.2	2
42	Eltrombopag; Romiplostim. Hospital Pharmacy, 2009, 44, 228-231.	1.0	0
43	Purpura thrombopénique immunologique chronique deÂl'adulte. Hematologie, 2009, 15, 148-153.	0.0	0
44	A Review on the Use of Eltrombopag in Patients with Advanced Liver Disease. Clinical Medicine Therapeutics, 2009, 1, CMT.S2267.	0.1	0
45	Chronic Immune Thrombocytopenic Purpura. , 2009, , 481-486.		0
46	Thrombocytopenia, an Important Interfering Factor of Antiviral Therapy and Hepatocellular Carcinoma Treatment for Chronic Liver Diseases. Kurume Medical Journal, 2009, 56, 9-15.	0.1	8
47	Medical treatments for idiopathic thrombocytopenic purpura during pregnancy. The Cochrane Library, 2009, , CD007722.	2.8	4
48	Nitric oxide in immune thrombocytopenic purpura. Hematology, 2009, 14, 59-62.	1.5	9
49	Challenges and priorities for patients with immune thrombocytopenic purpura and their physicians. Pharmaceuticals Policy and Law, 2009, 11, 299-305.	0.1	Ο
50	Maladies Hémorragiques Acquises et Thrombopénies. , 2009, , 72-126.		0
51	Eltrombopag: A Thrombopoietin Receptor Agonist for Idiopathic Thrombocytopenic Purpura. Journal of Pharmacy Technology, 2009, 25, 176-182.	1.0	0
52	Chronic Idiopathic Thrombocytopenic Purpura: Mechanisms of Pathogenesis. Oncologist, 2009, 14, 12-21.	3.7	79
53	Autoimmune cytopenias. Medicine, 2009, 37, 159-163.	0.4	6
54	Immune thrombocytopenic purpura: the treatment paradigm. European Journal of Haematology, 2009, 82, 13-19.	2.2	15
55	Development of thrombopoietin receptor agonists for clinical use. Journal of Thrombosis and Haemostasis, 2009, 7, 239-244.	3.8	32
56	Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: Two single-dose, open-label, randomized-sequence, crossover studies. Clinical Therapeutics, 2009, 31, 764-776.	2.5	72
57	Thrombocytopenia with absent radii (TAR) syndrome: from hemopoietic progenitor to mesenchymal stromal cell disease?. Experimental Hematology, 2009, 37, 1-7.	0.4	31

#	Article	IF	CITATIONS
58	Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function. Experimental Hematology, 2009, 37, 1030-1037.	0.4	90
59	Systolic blood pressure peak during maximal exercise testing: A possible determinant of endothelial turnover in healthy subjects. American Journal of Hematology, 2009, 84, 449-450.	4.1	1
60	Familial sideroblastic anemia associated with cardiac atrial septal defect. American Journal of Hematology, 2009, 84, 451-452.	4.1	0
61	Essential thrombocythemia in patients with platelet counts below 600x10 ⁹ /L: Applicability of the 2008 World Health Organization diagnostic criteria revision proposal. American Journal of Hematology, 2009, 84, 452-454.	4.1	2
62	Reappearance of acute myeloid leukemia after almost 23 years of continuous complete remission. American Journal of Hematology, 2009, 84, 455-457.	4.1	2
63	Successful treatment of cyclic thrombocytopenia with thrombopoietinâ€mimetic agents: A report of two patients. American Journal of Hematology, 2009, 84, 459-461.	4.1	10
64	Gemcitabineâ€based combination chemotherapy as salvage treatment for refractory or relapsing aggressive nonâ€Hodgkin's lymphoma. American Journal of Hematology, 2009, 84, 457-459.	4.1	1
65	HLA type and risk of alloimmunization in sickle cell disease. American Journal of Hematology, 2009, 84, 462-464.	4.1	46
66	Improvement in hemolysis and pulmonary arterial systolic pressure in adult patients with sickle cell disease during treatment with hydroxyurea. American Journal of Hematology, 2009, 84, 529-531.	4.1	37
67	Sequential evaluation of serum hepcidin in anemic myeloma patients: Study of correlations with myeloma treatment, disease variables, and anemia response. American Journal of Hematology, 2009, 84, 524-526.	4.1	18
68	DHFR 19â€bp insertion/deletion polymorphism and MTHFR C677T in adult acute lymphoblastic leukaemia: Is the risk reduction due to intracellular folate unbalancing?. American Journal of Hematology, 2009, 84, 526-529.	4.1	21
69	FLT3 mutations have no prognostic impact in elderly patients with acute myeloid leukemia and normal karyotype. American Journal of Hematology, 2009, 84, 532-534.	4.1	18
70	Overexpression of nucleolin in engrafted acute myelogenous leukemia cells. American Journal of Hematology, 2009, 84, 535-537.	4.1	10
71	Quantifying the reduction in immunoglobulin use over time in patients with chronic immune thrombocytopenic purpura receiving romiplostim (AMG 531). American Journal of Hematology, 2009, 84, 538-540.	4.1	20
72	Cost and mortality associated with hospitalizations in patients with immune thrombocytopenic purpura. American Journal of Hematology, 2009, 84, 631-635.	4.1	42
73	Shortâ€ŧerm and longâ€ŧerm failure of laparoscopic splenectomy in adult immune thrombocytopenic purpura patients: A systematic review. American Journal of Hematology, 2009, 84, 743-748.	4.1	84
74	Stimulating platelet production to raise platelet count in immune thrombocytopenic purpura: A novel approach. Indian Journal of Pediatrics, 2009, 76, 1065-1066.	0.8	0
75	Role of growth factors and thrombopoietic agents in the treatment of chronic hepatitis C. Current Gastroenterology Reports, 2009, 11, 5-14.	2.5	7

	CITATION	CITATION REPORT	
#	Article	IF	Citations
77	6â€mercaptopurine: Teaching an old drug new tricks. Pediatric Blood and Cancer, 2009, 52, 5-6.	1.5	3
78	Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production. British Journal of Haematology, 2009, 146, 585-596.	2.5	230
79	Platelets contribute to the reduction of liver fibrosis in mice. Journal of Gastroenterology and Hepatology (Australia), 2009, 24, 78-89.	2.8	94
80	Primary immune thrombocytopenia: understanding pathogenesis is the key to better treatments. Journal of Thrombosis and Haemostasis, 2009, 7, 319-321.	3.8	16
81	Preclinical Activity of Eltrombopag (SB-497115), an Oral, Nonpeptide Thrombopoietin Receptor Agonist. Stem Cells, 2009, 27, 424-430.	3.2	243
82	Eltrombopag: the discovery of a second generation thrombopoietin-receptor agonist. Expert Opinion on Drug Discovery, 2009, 4, 85-93.	5.0	12
83	Infectious Causes of Chronic Immune Thrombocytopenia. Hematology/Oncology Clinics of North America, 2009, 23, 1275-1297.	2.2	62
84	Traditional and New Approaches to the Management of Immune Thrombocytopenia: Issues of When and Who to Treat. Hematology/Oncology Clinics of North America, 2009, 23, 1329-1341.	2.2	5
85	Hematopoietic growth factor mimetics: From concept to clinic. Cytokine and Growth Factor Reviews, 2009, 20, 87-94.	7.2	28
86	Thrombopoietin in normal and neoplastic stem cell development. Best Practice and Research in Clinical Haematology, 2009, 22, 495-499.	1.7	3
89	An herbal decoction of Radix astragali and Radix angelicae sinensis promotes hematopoiesis and thrombopoiesis. Journal of Ethnopharmacology, 2009, 124, 87-97.	4.1	61
90	Eltrombopag. Drugs, 2009, 69, 567-576.	10.9	47
91	New Thrombopoietic Growth Factors. Clinical Lymphoma and Myeloma, 2009, 9, S347-S356.	1.4	95
92	Thrombopoietin and Thrombopoietin Mimetics in the Treatment of Thrombocytopenia. Annual Review of Medicine, 2009, 60, 193-206.	12.2	164
93	New options after first-line therapy for chronic immune thrombocytopenic purpura. American Journal of Health-System Pharmacy, 2009, 66, S11-S21.	1.0	11
94	Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood, 2009, 113, 2386-2393.	1.4	2,128
95	ITP in Elderly Patients: Practicing With S. Gerald Sandler, MD. Community Oncology, 2009, 6, 571-572.	0.2	0
96	Therapeutic Approaches to Secondary Immune Thrombocytopenic Purpura. Seminars in Hematology, 2009, 46, S44-S58.	3.4	16

#	Article	IF	CITATIONS
97	Therapeutic Strategies for Hepatitis- and Other Infection-Related Immune Thrombocytopenias. Seminars in Hematology, 2009, 46, S15-S25.	3.4	18
98	New-generation drugs that stimulate platelet production in chronic immune thrombocytopenic purpura. Lancet, The, 2009, 373, 1562-1569.	13.7	65
99	Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet, The, 2009, 373, 641-648.	13.7	493
100	Thrombopoietin and Platelet Production in Chronic Immune Thrombocytopenia. Hematology/Oncology Clinics of North America, 2009, 23, 1193-1211.	2.2	60
101	Chronic Immune Thrombocytopenia in Children: Epidemiology and Clinical Presentation. Hematology/Oncology Clinics of North America, 2009, 23, 1223-1238.	2.2	15
102	Thrombopoietin Agonists for the Treatment of Thrombocytopenia in Liver Disease and Hepatitis C. Clinics in Liver Disease, 2009, 13, 487-501.	2.1	13
103	Severe autoimmune cytopenias in treatment-naive hepatitis C virus infection: clinical description of 16 cases. European Journal of Gastroenterology and Hepatology, 2009, 21, 245-253.	1.6	22
104	Thrombopoietin receptor agonists in the treatment of thrombocytopenia. Current Opinion in Hematology, 2009, 16, 357-364.	2.5	11
105	1. An Oral Platelet Growth Factor. The Journal of the Japanese Society of Internal Medicine, 2009, 98, 1662-1668.	0.0	0
106	1. Idiopathic Thrombocytopenic Purpura. The Journal of the Japanese Society of Internal Medicine, 2009, 98, 1619-1626.	0.0	3
107	Hematopoietic Growth Factors (Cytokines). , 0, , 498-507.		0
109	A Syk inhibitor for sick platelets?. Blood, 2009, 113, 3133-3134.	1.4	1
110	Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood, 2009, 113, 2161-2171.	1.4	406
111	Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood, 2009, 113, 3154-3160.	1.4	229
112	The VWD2B saga continues to Montreal. Blood, 2009, 113, 3134-3135.	1.4	2
113	Intracranial hemorrhage (ICH) in children with immune thrombocytopenia (ITP): study of 40 cases. Blood, 2009, 114, 4777-4783.	1.4	184
114	Platelet factor 4 regulates megakaryopoiesis through low-density lipoprotein receptor–related protein 1 (LRP1) on megakaryocytes. Blood, 2009, 114, 2290-2298.	1.4	51
115	Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. Blood, 2009, 114, 3899-3908.	1.4	119

#	Articif	IF	Citations
116	Thrombocytopenia and Platelet Transfusion. , 0, , 199-210.		1
117	Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Yearbook of Pediatrics, 2009, 2009, 78-81.	0.2	1
118	Eltrombopag (Promacta), a Thrombopoetin Receptor Agonist for the Treatment of Thrombocytopenia: Current and Future Considerations. American Journal of Therapeutics, 2010, 17, 68-74.	0.9	11
119	Appropriate hospital management of adult immune thrombocytopenic purpura patients in major Italian institutions in 2000–2002: a retrospective analysis. Blood Coagulation and Fibrinolysis, 2010, 21, 77-84.	1.0	10
121	Non-Hodgkin's Lymphomas. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 288-334.	4.9	233
123	Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood, 2010, 115, 2755-2762.	1.4	242
124	Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. Blood, 2010, 116, 4639-4645.	1.4	262
125	Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations. Blood, 2010, 116, 5832-5837.	1.4	141
126	ITP: Tregs come to the rescue. Blood, 2010, 116, 4388-4390.	1.4	4
127	Moving towards a new era in the management of chronic immune thrombocytopenia. Annals of Hematology, 2010, 89, 87-93.	1.8	0
128	Mechanisms of platelet recovery in ITP associated with therapy. Annals of Hematology, 2010, 89, 31-35.	1.8	8
129	Chronic immune thrombocytopenic purpura—who needs medication?. Annals of Hematology, 2010, 89, 61-65.	1.8	16
130	Treatment of chronic immune thrombocytopenic purpura in adults. Annals of Hematology, 2010, 89, 55-60.	1.8	13
131	Eltrombopag: an update on the novel, non-peptide thrombopoietin receptor agonist for the treatment of immune thrombocytopenia. Annals of Hematology, 2010, 89, 67-74.	1.8	48
132	Should medical treatment options be exhausted before splenectomy is performed in adult ITP patients? A debate. Annals of Hematology, 2010, 89, 1185-1195.	1.8	24
134	Eltrombopag, an oral thrombopoietin receptor agonist, has no impact on the pharmacokinetic profile of probe drugs for cytochrome P450 isoenzymes CYP3A4, CYP1A2, CYP2C9 and CYP2C19 in healthy men: a cocktail analysis. European Journal of Clinical Pharmacology, 2010, 66, 67-76.	1.9	13
136	Treatment Options for Chronic Refractory Idiopathic Thrombocytopenic Purpura in Adults: Focus on Romiplostim and Eltrombopag. Pharmacotherapy, 2010, 30, 666-683.	2.6	26
137	The geoepidemiology of immune thrombocytopenic purpura. Autoimmunity Reviews, 2010, 9, A342-A349.	5.8	41

#	Article	IF	CITATIONS
138	Hepatosplenic T cell lymphoma responsive to 2′-deoxycoformycin therapy. American Journal of Hematology, 2010, 85, 727-729.	4.1	16
139	Screening coagulation testing using the APTT: Which reagent to choose?. American Journal of Hematology, 2010, 85, 726-726.	4.1	7
140	Acute renal failure in a patient with antiphospholipid syndrome and immune thrombocytopenic purpura treated with eltrombopag. American Journal of Hematology, 2010, 85, 724-726.	4.1	14
141	Clinical significance of clonality and Epsteinâ€Barr virus infection in adult patients with hemophagocytic lymphohistiocytosis. American Journal of Hematology, 2010, 85, 719-722.	4.1	51
142	Acute life-threatening cardiovascular toxicity with umbilical cord blood infusion: The role of dextran. American Journal of Hematology, 2010, 85, 722-724.	4.1	13
143	Alteration of cohesin genes in myeloid diseases. American Journal of Hematology, 2010, 85, 717-719.	4.1	46
144	Effective management of accelerated phase myelofibrosis with lowâ€dose splenic radiotherapy. American Journal of Hematology, 2010, 85, 715-716.	4.1	18
145	Acute leukemia presenting with extramedullary diseases and completely normal hemogram: An extremely unusual manifestation unique to preâ€B ALL. American Journal of Hematology, 2010, 85, 729-731.	4.1	13
146	Incorporating novel agents in the treatment of myelodysplastic syndromes. Leukemia Research, 2010, 34, 6-17.	0.8	10
147	Reduced proliferation of non-megakaryocytic acute myelogenous leukemia and other leukemia and lymphoma cell lines in response to eltrombopag. Leukemia Research, 2010, 34, 1224-1231.	0.8	39
148	Eltrombopag (75 mg) does not induce photosensitivity: results of a clinical pharmacology trial. Photodermatology Photoimmunology and Photomedicine, 2010, 26, 243-249.	1.5	9
149	Pharmacodynamic Effects of Haematopoietic Cytokines: The View of a Clinical Oncologist. Basic and Clinical Pharmacology and Toxicology, 2010, 106, 210-214.	2.5	4
150	Eltrombopag does not affect cardiac repolarization: results from a definitive QTc study in healthy subjects. British Journal of Clinical Pharmacology, 2010, 70, 24-33.	2.4	20
151	Thrombopoietic effect of VPAC1 inhibition during megakaryopoiesis. British Journal of Haematology, 2010, 151, 54-61.	2.5	14
152	Blood Disorders in the Elderly. , 2010, , 775-790.		0
153	Management of chronic immune thrombocytopenic purpura: targeting insufficient megakaryopoiesis as a novel therapeutic principle. Biologics: Targets and Therapy, 2010, 4, 139.	3.2	17
154	A review of immune thrombocytopenic purpura: focus on the novel thrombopoietin agonists. Journal of Blood Medicine, 2010, 1, 21.	1.7	6
155	Romiplostim: Therapeutic Value in Chronic Immune Thrombocytopenic Purpura. Clinical Medicine Insights Therapeutics, 2010, 2, CMT.S4618.	0.4	0

~		~	
(11		1JED(דסר
\sim	IAL	NLP	ואכ

#	Article	IF	CITATIONS
156	Long-term management of chronic immune thrombocytopenic purpura in adults. International Journal of General Medicine, 2010, 3, 305.	1.8	9
157	Review Article: Second-generation thrombopoietin agents for treatment of chronic idiopathic thrombocytopenic purpura in adults. Journal of Oncology Pharmacy Practice, 2010, 16, 89-103.	0.9	11
158	Eltrombopag: A Novel Oral Thrombopoietin Receptor Agonist. Annals of Pharmacotherapy, 2010, 44, 1072-1079.	1.9	19
159	Considerations in the management of hepatitis C virus-related thrombocytopenia with eltrombopag. Saudi Journal of Gastroenterology, 2010, 16, 51.	1.1	19
160	The Hematopoietic Growth Factors in the Myelodysplastic Syndromes. Cancer Treatment and Research, 2010, 157, 363-382.	0.5	1
162	Safety of the Thrombopoiesis-Stimulating Agents for the Treatment of Immune Thrombocytopenia. Current Drug Safety, 2010, 5, 171-181.	0.6	25
163	A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin/paclitaxel for advanced solid tumors. Current Medical Research and Opinion, 2010, 26, 2339-2346.	1.9	51
164	Childhood Immune Thrombocytopenic Purpura: Diagnosis and Management. Hematology/Oncology Clinics of North America, 2010, 24, 249-273.	2.2	66
165	To Market, To Market—2009. Annual Reports in Medicinal Chemistry, 2010, , 466-537.	0.9	4
166	Myelodysplastic Syndromes: What a Primary Care Physician Needs to Know. Disease-a-Month, 2010, 56, 468-478.	1.1	1
167	Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedside. British Journal of Haematology, 2010, 150, 9-20.	2.5	73
168	International consensus report on the investigation and management of primary immune thrombocytopenia. Blood, 2010, 115, 168-186.	1.4	1,802
169	Radiation victim management and the haematologist in the future: Time to revisit therapeutic guidelines?. International Journal of Radiation Biology, 2010, 86, 636-648.	1.8	63
170	Toxicities of the Thrombopoietic Growth Factors. Seminars in Hematology, 2010, 47, 289-298.	3.4	49
171	Thrombopoietic Agents in Immune Thrombocytopenia. Seminars in Hematology, 2010, 47, 258-265.	3.4	15
172	Use of Thrombopoietic Agents for the Thrombocytopenia of Liver Disease. Seminars in Hematology, 2010, 47, 266-273.	3.4	16
173	The management of peripheral blood cytopenias in systemic lupus erythematosus. Rheumatology, 2010, 49, 2243-2254.	1.9	117
174	Current status of thrombopoietic agents. Expert Review of Hematology, 2010, 3, 217-225.	2.2	5

#	Article	IF	CITATIONS
175	Increasing platelets without transfusion: is it time to introduce novel thrombopoietic agents in neonatal care?. Journal of Perinatology, 2010, 30, 765-769.	2.0	25
176	Eltrombopag: a guide to its use in chronic immune (idiopathic) thrombocytopenic purpura. Drugs and Therapy Perspectives, 2011, 27, 5-8.	0.6	Ο
177	Spotlight on Eltrombopag in Treatment-Refractory Chronic Primary Immune Thrombocytopeniaâ€. BioDrugs, 2011, 25, 401-404.	4.6	4
178	Durability and factors associated with long term response after splenectomy for primary immune thrombocytopenia (ITP) and outcome of relapsed or refractory patients. Platelets, 2011, 22, 1-6.	2.3	24
179	Investigations of Hydrazine Cleavage of Eltrombopag in Humans. Drug Metabolism and Disposition, 2011, 39, 1747-1754.	3.3	13
181	TPO receptor agonist for chronic idiopathic thrombocytopenic purpura. The Cochrane Library, 2011, 2011, CD008235.	2.8	40
183	Eltrombopag. Drugs, 2011, 71, 1333-1353.	10.9	27
184	Thrombopoietin-Receptor Agonists for Primary Immune Thrombocytopenia. New England Journal of Medicine, 2011, 365, 734-741.	27.0	109
185	Hematopoietic Growth Factors in Oncology. Cancer Treatment and Research, 2011, , .	0.5	5
186	Eltrombopag for the treatment of immune thrombocytopenia. Expert Review of Hematology, 2011, 4, 261-269.	2.2	13
187	Platelet production and destruction in liver cirrhosis. Journal of Hepatology, 2011, 54, 894-900.	3.7	107
188	Current treatment options for primary immune thrombocytopenia. Expert Review of Hematology, 2011, 4, 107-118.	2.2	21
190	Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet, The, 2011, 377, 393-402.	13.7	480
191	Eltrombopag for chronic immune thrombocytopenia – Authors' reply. Lancet, The, 2011, 377, 1919-1920.	13.7	0
192	A role of platelets in liver fibrosis. Japanese Journal of Thrombosis and Hemostasis, 2011, 22, 71-76.	0.1	0
194	Danazol improves thrombocytopenia in HCV patients treated with peginterferon and ribavirin. Annals of Hepatology, 2011, 10, 458-468.	1.5	13
195	Pharmacokinetics and Pharmacodynamics of Eltrombopag in Healthy Japanese Males. Japanese Journal of Clinical Pharmacology and Therapeutics, 2011, 42, 11-20.	0.1	19
196	Eltrombopag for the treatment of chronic immune thrombocytopenia. Clinical Investigation, 2011, 1, 295-303.	0.0	1

#	Article	IF	CITATIONS
197	Immune (idiopathic) thrombocytopenic purpura in a 21-year-old student. JAAPA: Official Journal of the American Academy of Physician Assistants, 2011, 24, E1-E3.	0.3	1
198	A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. Blood, 2011, 118, 28-36.	1.4	195
199	Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia. Blood, 2011, 117, 5723-5732.	1.4	130
200	Non-Hodgkin's Lymphomas. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 484-560.	4.9	161
201	Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers. British Journal of Clinical Pharmacology, 2011, 72, 321-329.	2.4	63
202	Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents. British Journal of Haematology, 2011, 155, 248-255.	2.5	34
203	Eltrombopag: An Oral Thrombopoietin Receptor Agonist for the Treatment of Idiopathic Thrombocytopenic Purpura. Clinical Therapeutics, 2011, 33, 1560-1576.	2.5	23
204	Validation of the FACIT-fatigue subscale, selected items from FACT-thrombocytopenia, and the SF-36v2 in patients with chronic immune thrombocytopenia. Quality of Life Research, 2011, 20, 1737-1744.	3.1	42
205	Accessory splenectomy for refractory immune thrombocytopenic purpura. American Journal of Hematology, 2011, 86, 520-523.	4.1	11
206	Thrombopoietic growth factors in the treatment of immune thrombocytopenic purpura. Critical Reviews in Oncology/Hematology, 2011, 77, 172-183.	4.4	15
207	Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome. Leukemia Research, 2011, 35, 323-328.	0.8	36
208	Childhood Immune Thrombocytopenia: A Changing Therapeutic Landscape. Seminars in Thrombosis and Hemostasis, 2011, 37, 745-755.	2.7	23
209	Population Pharmacokinetics of Eltrombopag in Healthy Subjects and Patients With Chronic Idiopathic Thrombocytopenic Purpura. Journal of Clinical Pharmacology, 2011, 51, 842-856.	2.0	72
210	Pharmacokinetics and Pharmacodynamics Clinical Pharmacokinetics, Platelet Response, and Safety of Eltrombopag at Supratherapeutic Doses of up to 200 mg Once Daily in Healthy Volunteers. Journal of Clinical Pharmacology, 2011, 51, 301-308.	2.0	24
211	Population PK/PD Modeling of Eltrombopag in Healthy Volunteers and Patients With Immune Thrombocytopenic Purpura and Optimization of Response-Guided Dosing. Journal of Clinical Pharmacology, 2011, 51, 1403-1417.	2.0	35
212	Effect of Hepatic or Renal Impairment on Eltrombopag Pharmacokinetics. Journal of Clinical Pharmacology, 2011, 51, 739-750.	2.0	31
213	Metabolism and Disposition of Eltrombopag, an Oral, Nonpeptide Thrombopoietin Receptor Agonist, in Healthy Human Subjects. Drug Metabolism and Disposition, 2011, 39, 1734-1746.	3.3	40
214	The European Medicines Agency review of eltrombopag (Revolade) for the treatment of adult chronic immune (idiopathic) thrombocytopenic purpura: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Haematologica, 2011, 96, e33-e40.	3.5	26

#	Article	IF	Citations
215	Infection-Related Transient Loss of Response and Other Early Side Effects in Chronic ITP during Treatment with Thrombopoietin Mimetics. Onkologie, 2011, 34, 10-13.	0.8	2
216	Diagnosis and Management of Immune Thrombocytopenia in the Era of Thrombopoietin Mimetics. Hematology American Society of Hematology Education Program, 2011, 2011, 384-390.	2.5	36
217	Pharmacokinetics and Hepatic Uptake of Eltrombopag, a Novel Platelet-Increasing Agent. Drug Metabolism and Disposition, 2011, 39, 1088-1096.	3.3	28
218	Immune-Related Disorders and Extrahepatic Diseases in Chronic HCV Infection. Clinical and Developmental Immunology, 2012, 2012, 1-2.	3.3	4
219	Thrombopoietin-receptor agonists. Current Opinion in Hematology, 2012, 19, 392-398.	2.5	36
220	Use of Romiplostim in a Hemodialysis Patient with Primary Immune Thrombocytopenia. Annals of Pharmacotherapy, 2012, 46, e31-e31.	1.9	4
221	Phenotyping bleeding. Current Opinion in Hematology, 2012, 19, 406-412.	2.5	4
222	Clinical and research issues in neonatal anemia and thrombocytopenia. Current Opinion in Pediatrics, 2012, 24, 16-22.	2.0	10
223	ROMIPLOSTIM AND ELTROMBOPAG FOR IMMUNE THROMBOCYTOPENIA: METHODS FOR INDIRECT COMPARISON. International Journal of Technology Assessment in Health Care, 2012, 28, 249-258.	0.5	30
224	Thrombopoietin receptor agonist therapy in primary immune thrombocytopenia is associated with bone marrow hypercellularity and mild reticulin fibrosis but not other stromal abnormalities. Modern Pathology, 2012, 25, 65-74.	5.5	37
225	Immunological HCV-Associated Thrombocytopenia: Short Review. Clinical and Developmental Immunology, 2012, 2012, 1-5.	3.3	12
226	Assessment of the Pharmacokinetic Interaction between Eltrombopag and Lopinavir-Ritonavir in Healthy Adult Subjects. Antimicrobial Agents and Chemotherapy, 2012, 56, 2846-2851.	3.2	23
227	Eltrombopag, a thrombopoietin- receptor agonist in the treatment of adult chronic immune thrombocytopenia: a review of the efficacy and safety profile. Therapeutic Advances in Hematology, 2012, 3, 155-164.	2.5	42
228	Human capital contracts for global health. Aids, 2012, 26, 1979-1980.	2.2	2
229	Similar virologic response after initiation of triple-class antiretroviral therapy in primary and chronic HIV infection. Aids, 2012, 26, 1974-1977.	2.2	0
231	13. TPO Receptor Agonist in the Treatment of Primary Immune Thrombocytopenia. The Journal of the Japanese Society of Internal Medicine, 2012, 101, 135b-136a.	0.0	Ο
232	Successful use of eltrombopag without splenectomy in refractory HIV-related immune reconstitution thrombocytopenia. Aids, 2012, 26, 1977-1979.	2.2	8
233	Alleles at rs4273729 in the chromosome 6 do not predict response to peg-interferon-α and ribavirin therapy in hepatitis C virus/HIV-1Ⱐcoinfected patients. Aids, 2012, 26, 1973-1974.	2.2	3

#	Article	IF	CITATIONS
234	Defective regulatory B-cell compartment in patients with immune thrombocytopenia. Blood, 2012, 120, 3318-3325.	1.4	164
235	Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. Blood, 2012, 120, 386-394.	1.4	146
236	Risk and prognosis of adult primary immune thrombocytopenia. Expert Review of Hematology, 2012, 5, 219-228.	2.2	10
237	Venous thromboembolism and coagulation activity in patients with immune thrombocytopenia treated with thrombopoietin receptor agonists. British Journal of Haematology, 2012, 158, 811-814.	2.5	24
238	Demand-adapted regulation of early hematopoiesis in infection and inflammation. Blood, 2012, 119, 2991-3002.	1.4	351
239	How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. Blood, 2012, 120, 960-969.	1.4	197
240	Efficacy and safety of eltrombopag in Japanese patients with chronic liver disease and thrombocytopenia: a randomized, open-label, phase II study. Journal of Gastroenterology, 2012, 47, 1342-1351.	5.1	25
241	A Promising New Treatment for Refractory Aplastic Anemia. New England Journal of Medicine, 2012, 367, 74-75.	27.0	4
242	In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation. Blood, 2012, 119, 4066-4072.	1.4	86
243	Selective validation of the WHO Bleeding Scale in patients with chronic immune thrombocytopenia. Current Medical Research and Opinion, 2012, 28, 79-87.	1.9	82
244	Patient-reported treatment burden of chronic immune thrombocytopenia therapies. BMC Blood Disorders, 2012, 12, 2.	0.9	25
245	Why Does My Patient Have Thrombocytopenia?. Hematology/Oncology Clinics of North America, 2012, 26, 231-252.	2.2	12
246	TGFβ1 and sCTLA-4 levels are increased in eltrombopag-exposed patients with ITP. Thrombosis Research, 2012, 130, 415-419.	1.7	11
247	Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: systematic review and meta-analysis of randomized controlled trials. Medicina ClÃnica, 2012, 139, 421-429.	0.6	41
248	Prolonged remission from eltrombopag in chronic refractory idiopathic thrombocytopenic purpura. International Journal of Hematology, 2012, 96, 380-382.	1.6	7
249	A multicenter randomized controlled trial of recombinant human thrombopoietin treatment in patients with primary immune thrombocytopenia. International Journal of Hematology, 2012, 96, 222-228.	1.6	77
250	Eltrombopag for the Treatment of Chronic Immune or Idiopathic Thrombocytopenic Purpura. Pharmacoeconomics, 2012, 30, 483-495.	3.3	38
251	Romiplostim therapy in children with unresponsive chronic immune thrombocytopenia. Platelets, 2012, 23, 264-273.	2.3	34

#	Article	IF	CITATIONS
252	Eltrombopag and Improved Hematopoiesis in Refractory Aplastic Anemia. New England Journal of Medicine, 2012, 367, 11-19.	27.0	454
253	Thrombopoietin-receptor agonists in haematological disorders: The Danish experience. Platelets, 2012, 23, 423-429.	2.3	23
254	Immune thrombocytopenic purpura: Historical perspective, current status, recent advances and future directions. Indian Pediatrics, 2012, 49, 811-818.	0.4	15
255	Acquired thrombocytopenia. , 0, , 157-171.		0
256	Romiplostim as early treatment of immune thrombocytopenia with severe immunodeficiency. Hematology Reports, 2012, 4, e10.	0.8	3
257	Severe Immune Thrombocytopenic Purpura Treated with Plasma Exchange. Kathmandu University Medical Journal, 2012, 10, 77-82.	0.2	6
258	Use of eltrombopag, a thrombopoietin receptor agonist, in postâ€ŧransplantation thrombocytopenia. American Journal of Hematology, 2012, 87, 743-745.	4.1	43
259	Bleeding and mortality outcomes in ITP clinical trials: A review of thrombopoietin mimetics data. American Journal of Hematology, 2012, 87, 984-987.	4.1	16
260	Therapeutic options for immuneâ€mediated thrombocytopenia. Journal of Veterinary Emergency and Critical Care, 2012, 22, 59-72.	1.1	12
261	Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations. Journal of Clinical Pharmacy and Therapeutics, 2012, 37, 729-732.	1.5	19
262	A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia. Journal of Thrombosis and Haemostasis, 2012, 10, 799-806.	3.8	81
263	Duration and morbidity of chronic immune thrombocytopenic purpura in children: fiveâ€year followâ€up of a Nordic cohort. Acta Paediatrica, International Journal of Paediatrics, 2012, 101, 761-766.	1.5	43
264	Eltrombopag, a thrombopoietin receptor agonist, enhances human umbilical cord blood hematopoietic stem/primitive progenitor cell expansion and promotes multi-lineage hematopoiesis. Stem Cell Research, 2012, 9, 77-86.	0.7	59
265	Eltrombopag named patient programme for patients with chronic immune thrombocytopenia. British Journal of Haematology, 2012, 157, 259-260.	2.5	2
266	Short―and longâ€ŧerm risks of splenectomy for benign haematological disorders: should we revisit the indications?. British Journal of Haematology, 2012, 158, 16-29.	2.5	99
267	Sequence of treatments for adults with primary immune thrombocytopenia. American Journal of Hematology, 2012, 87, S12-5.	4.1	15
268	Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide. BMC Cancer, 2013, 13, 121.	2.6	22
269	Oral eltrombopag for up to three years is safe and well-tolerated in Japanese patients with previously treated chronic immune thrombocytopenia: an open-label, extension study. International Journal of Hematology, 2013, 98, 323-330.	1.6	21

#	Article	IF	CITATIONS
270	Predictive factors associated with long-term effects of laparoscopic splenectomy for chronic immune thrombocytopenia. International Journal of Hematology, 2013, 97, 610-616.	1.6	17
271	Lowâ€dose antiâ€ <scp>CD</scp> 20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I study. British Journal of Haematology, 2013, 162, 693-701.	2.5	25
272	Population PK/PD modeling of eltrombopag in subjects with advanced solid tumors with chemotherapy-induced thrombocytopenia. Cancer Chemotherapy and Pharmacology, 2013, 71, 1507-1520.	2.3	19
273	Valproic acid for the treatment of low-risk myelodysplastic syndromes: A case report and a review of the literature. Leukemia Research Reports, 2013, 2, 44-46.	0.4	0
274	Thrombopoietin Receptor Agonists in Primary Immune Thrombocytopenia. Seminars in Hematology, 2013, 50, S18-S21.	3.4	39
275	Targeting the SYK–BTK axis for the treatment of immunological and hematological disorders. , 2013, 138, 294-309.		56
276	Contemporary treatment of immune thrombocytopenia. Expert Review of Hematology, 2013, 6, 697-712.	2.2	4
277	Safety and efficacy of romiplostim in patients with eltrombopagâ€resistant or â€intolerant immune thrombocytopenia. British Journal of Haematology, 2013, 163, 286-289.	2.5	10
278	Eltrombopag per il trattamento della porpora trombocitopenica immune o idiopatica cronica. Pharmacoeconomics Italian Research Articles, 2013, 15, 143-152.	0.2	0
279	Repeated shortâ€ŧerm use of eltrombopag in patients with chronic immune thrombocytopenia (ITP). British Journal of Haematology, 2013, 160, 538-546.	2.5	58
280	Preoperative use of romiplostim in thrombocytopenic patients with chronic hepatitis <scp>C</scp> and liver cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 335-341.	2.8	50
281	A Phase 1 Trial of Eltrombopag in Patients Undergoing Stem Cell Transplantation after Total Body Irradiation. Biology of Blood and Marrow Transplantation, 2013, 19, 1745-1752.	2.0	27
282	Exome sequencing reveals a thrombopoietin ligand mutation in a Micronesian family with autosomal recessive aplastic anemia. Blood, 2013, 122, 3440-3449.	1.4	61
283	MaÅ,opÅ,ytkowość – wskazania do zastosowania cytokin pÅ,ytkotwórczych. Acta Haematologica Polonica, 2013, 44, 130-134.	0.3	0
284	Severe cutaneous toxicity related to Eltrombopag. British Journal of Haematology, 2013, 160, 412-414.	2.5	13
285	Immune Thrombocytopenia (ITP). , 2013, , 819-833.		6
286	Longâ€ŧerm treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. British Journal of Haematology, 2013, 161, 411-423.	2.5	234
287	High response rate to lowâ€dose rituximab plus highâ€dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia. European Journal of Haematology, 2013, 90, 494-500.	2.2	46

#	Article	IF	CITATIONS
288	Nontransfusional approach to increased platelet count in patients with cirrhosis and thrombocytopenia. Hepatology, 2013, 58, 1177-1180.	7.3	11
289	Autoimmunity and Novel Therapies in Immune-Mediated Thrombocytopenia. Seminars in Hematology, 2013, 50, S100-S108.	3.4	20
290	Advances in megakaryocytopoiesis and thrombopoiesis: from bench to bedside. British Journal of Haematology, 2013, 161, 778-793.	2.5	79
291	Immune Thrombocytopenia Nomenclature, Consensus Reports, and Guidelines: What Are the Consequences for Daily Practice and Clinical Research?. Seminars in Hematology, 2013, 50, S50-S54.	3.4	30
292	Do we know when to treat neonatal thrombocytopaenia?. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2013, 98, F380-F382.	2.8	9
293	General Aspects of Thrombocytopenia, Platelet Transfusions, and Thrombopoietic Growth Factors. , 2013, , 103-116.		10
294	Efficacy of eltrombopag in management of bleeding symptoms associated with chronic immune thrombocytopenia. Blood Coagulation and Fibrinolysis, 2013, 24, 284-296.	1.0	9
295	Eltrombopag for the treatment of thrombocytopenia in patients with malignant and non-malignant hematologic disorders. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 1667-1675.	3.3	10
296	Thrombopoietin levels in patients with disorders of platelet production: Diagnostic potential and utility in predicting response to TPO Receptor agonists. American Journal of Hematology, 2013, 88, 1041-1044.	4.1	70
297	Longâ€ŧerm safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials. European Journal of Haematology, 2013, 91, 423-436.	2.2	90
298	Primary Immune Thrombocytopenia. , 2013, , 117-131.		0
299	Current management of immune thrombocytopenia. Hematology American Society of Hematology Education Program, 2013, 2013, 276-282.	2.5	72
301	Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood, 2013, 121, 537-545.	1.4	295
302	Preferential splenic CD8+ T-cell activation in rituximab-nonresponder patients with immune thrombocytopenia. Blood, 2013, 122, 2477-2486.	1.4	42
303	A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia. Haematologica, 2013, 98, 881-887.	3.5	78
304	Function of eltrombopag-induced platelets compared to platelets from control patients with immune thrombocytopenia. Thrombosis and Haemostasis, 2013, 109, 676-683.	3.4	26
305	The role of eltrombopag in the management of hepatitis C virus-related thrombocytopenia. Hepatic Medicine: Evidence and Research, 2013, 5, 17.	2.5	11
306	RAD001-mediated STAT3 upregulation and megakaryocytic differentiation. Thrombosis and Haemostasis, 2013, 109, 540-549.	3.4	3

#	Article	IF	CITATIONS
307	Clinical Indications for Thrombopoietin and Thrombopoietin-Receptor Agonists. Transfusion Medicine and Hemotherapy, 2013, 40, 319-325.	1.6	54
308	Chronic Immune Thrombocytopenia. , 2013, , 641-646.		0
309	The Platelet as a Target for Damage. , 2014, , 3115-3138.		1
310	Effectiveness of Thrombopoietin-receptor Agonists in the Treatment of Refractory Immune Thrombocytopenia Associated to Systemic Lupus Erythematosus. Journal of Rheumatology, 2014, 41, 1895-1896.	2.0	19
311	The pharmacology and clinical application of thrombopoietin receptor agonists. International Journal of Hematology, 2014, 100, 529-539.	1.6	9
312	Megakaryocyte morphology and its impact in predicting response to steroid in immune thrombocytopenia. Platelets, 2014, 25, 526-531.	2.3	15
313	Usefulness of short-term eltrombopag treatment as a supportive treatment in hepatocellular carcinoma patients with cirrhosis and severe thrombocytopenia: A report of two cases. Oncology Letters, 2014, 7, 2130-2134.	1.8	4
314	Eltrombopag can overcome the anti-megakaryopoietic effects of lenalidomide without increasing proliferation of the malignant myelodysplastic syndrome/acute myelogenous leukemia clone. Leukemia and Lymphoma, 2014, 55, 2901-2906.	1.3	11
315	When is a seamless study desirable? Case studies from different pharmaceutical sponsors. Pharmaceutical Statistics, 2014, 13, 229-237.	1.3	36
316	Are adverse drug reaction patterns different between romiplostim and eltrombopag? 2009–2013 French PharmacoVigilance assessment. European Journal of Internal Medicine, 2014, 25, 777-780.	2.2	29
317	A pilot phase I dose finding safety study of the thrombopoietinâ€receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine. European Journal of Haematology, 2014, 93, 439-445.	2.2	29
318	The temporary use of thrombopoietinâ€receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study. British Journal of Haematology, 2014, 165, 865-869.	2.5	110
319	Hemostatic challenges in patients with chronic immune thrombocytopenia treated with eltrombopag. Platelets, 2014, 25, 55-61.	2.3	11
320	Thrombopoietic agents: There is still much to learn. Presse Medicale, 2014, 43, e69-e78.	1.9	15
321	Prednisone versus high-dose dexamethasone for untreated primary immune thrombocytopenia. A retrospective study of the Japan Hematology & Oncology Clinical Study Group. Journal of Thrombosis and Thrombolysis, 2014, 37, 279-286.	2.1	25
322	Eltrombopag therapy in newly diagnosed steroid non-responsive ITP patients. International Journal of Hematology, 2014, 99, 413-417.	1.6	23
323	Clinical practice: immune thrombocytopenia in paediatrics. European Journal of Pediatrics, 2014, 173, 163-172.	2.7	39
324	Interaction of Novel Platelet-Increasing Agent Eltrombopag with Rosuvastatin via Breast Cancer Resistance Protein in Humans. Drug Metabolism and Disposition, 2014, 42, 726-734.	3.3	22

	Ст	CITATION REPORT	
#	Article	IF	Citations
325	Small Molecules Targeting <i>in Vivo</i> Tissue Regeneration. ACS Chemical Biology, 2014, 9, 57-71.	3.4	36
326	Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood, 2014, 123, 1818-1825.	1.4	336
327	Eltrombopag for resistant immune thrombocytopenia secondary to chronic lymphocytic leukaemia. Internal Medicine Journal, 2014, 44, 697-699.	0.8	8
328	Eltrombopag: A Review of Its Use in the Treatment of Thrombocytopenia in Patients with Chronic Hepatitis C. Drugs, 2014, 74, 1961-1971.	10.9	12
329	Foxp3 methylation status in children with primary immune thrombocytopenia. Human Immunology, 2014, 75, 1115-1119.	2.4	17
330	Cardiac and pulmonary thrombosis during multidrug treatment in an idiopathic thrombocytopenic purpura patient. Platelets, 2014, 25, 69-70.	2.3	16
331	Successful platelet count recovery in lupus-associated thrombocytopenia with the thrombopoietin agonist eltrombopag. Clinical Rheumatology, 2014, 33, 1347-1349.	2.2	12
332	Thrombopoietic Agents for the Treatment of Persistent and Chronic Immune Thrombocytopenia in Children. Journal of Pediatrics, 2014, 165, 600-605.e4.	1.8	49
333	Thrombocytopenia in cancer patients. Thrombosis Research, 2014, 133, S63-S69.	1.7	89
334	Bone marrow fibrosis in 66 patients with immune thrombocytopenia treated with thrombopoietin-receptor agonists: a single-center, long-term follow-up. Haematologica, 2014, 99, 937-944.	3.5	84
335	A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Blood, 2014, 123, 3887-3894.	1.4	112
336	Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: Systematic review and meta-analysis of randomized controlled trials. Medicina ClÃnica (English Edition), 2015, 145, 511-519.	0.2	0
337	A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP. Blood, 2015, 125, 1541-1547.	1.4	100
338	Development and validation of a LC–MS/MS method for quantification of hetrombopag for pharmacokinetics study. SpringerPlus, 2015, 4, 652.	1.2	9
339	Are Risk Evaluation and Mitigation Strategies Associated With Less Off‣abel Use of Medications? Th Case of Immune Thrombocytopenia. Clinical Pharmacology and Therapeutics, 2015, 97, 186-193.	e 4.7	11
340	Chronic Lymphocytic Leukemia-associated Refractory Immune Thrombocytopenia Successfully Treated with Eltrombopag. Tumori, 2015, 101, e49-e50.	1.1	8
341	Eltrombopag Modulates Reactive Oxygen Species and Decreases Acute Myeloid Leukemia Cell Survival PLoS ONE, 2015, 10, e0126691.	. 2.5	33
342	Eltrombopag: a new treatment option for chronic refractory adult immune thrombocytopenia. Blood Research, 2015, 50, 1.	1.3	0

#	Article	IF	CITATIONS
343	Recombinant Human Thrombopoietin Alleviates Infection-Associated Thrombocytopenia. Clinical and Applied Thrombosis/Hemostasis, 2015, 21, 19-24.	1.7	5
344	Dental procedures in 24 patients with chronic immune thrombocytopenia in prospective clinical studies of eltrombopag. Platelets, 2015, 26, 93-96.	2.3	13
345	The non-peptide thrombopoietin receptor agonist eltrombopag stimulates megakaryopoiesis in bone marrow cells from patients with relapsed multiple myeloma. Journal of Hematology and Oncology, 2015, 8, 37.	17.0	10
346	Eltrombopag enhances platelet adhesion by upregulating the expression of glycoprotein VI in patients with chronic immune thrombocytopenic purpura. Translational Research, 2015, 166, 750-761.e4.	5.0	6
347	Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial. Lancet Haematology,the, 2015, 2, e417-e426.	4.6	64
348	The Eltrombopag antitumor effect on hepatocellular carcinoma. International Journal of Oncology, 2015, 47, 1696-1702.	3.3	21
350	Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim. International Journal of Hematology, 2015, 101, 255-263.	1.6	49
351	Thrombopoiesisâ€stimulating agents and myelodysplastic syndromes. British Journal of Haematology, 2015, 169, 309-323.	2.5	22
352	Sustained response after discontinuation of short-and medium-term treatment with eltrombopag in patients with immune thrombocytopenia. Platelets, 2015, 26, 83-86.	2.3	16
353	Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial. Lancet, The, 2015, 386, 1649-1658.	13.7	164
354	Thrombopoietin-receptor agonists in children with immune thrombocytopenia. Lancet, The, 2015, 386, 1606-1609.	13.7	3
356	Sustained remission of chronic immune thrombocytopenia after discontinuation of treatment with thrombopoietin-receptor agonists in adults. International Journal of Hematology, 2015, 102, 7-11.	1.6	45
357	Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia. American Journal of Hematology, 2015, 90, E40-3.	4.1	121
358	Successful treatment of severe thrombocytopenia with the use of thrombopoeitin receptor agonist eltrombopag in a patient with chronic myelomonocytic leukemia. Journal of Oncology Pharmacy Practice, 2015, 21, 74-75.	0.9	5
359	Design, synthesis of diaminopyrimidine inhibitors targeting IgE- and IgG-mediated activation of Fc receptor signaling. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 2122-2128.	2.2	8
360	Eltrombopag for treatment of thrombocytopenia-associated disorders. Expert Opinion on Pharmacotherapy, 2015, 16, 2243-2256.	1.8	16
361	Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: Systematic review and meta-analysis of randomized controlled trials. Medicina ClÂnica, 2015, 145, 511-519.	0.6	49
362	Population Pharmacokinetic and Pharmacodynamic Modeling and Effects on Platelet Counts of Different Dosages of Eltrombopag in Chinese Patients With Chronic Primary Immune Thrombocytopenia. Clinical Therapeutics, 2015, 37, 1382-1395.	2.5	11

	CITA	ATION REPORT	
#	Article	IF	Citations
363	Current Management of Primary Immune Thrombocytopenia. Advances in Therapy, 2015, 32, 875-887.	2.9	101
364	Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. Lancet Haematology,the, 2015, 2, e315-e325.	4.6	146
365	Thrombocytopenia in Pregnancy: Gestational Thrombocytopenia and Immune Thrombocytopenic Purpura. , 2015, , 261-277.		1
366	Will thrombopoietin receptor agonists become a treatment option for pediatric chronic immune thrombocytopenia in the future?. Clinical Investigation, 2015, 5, 287-296.	0.0	0
367	Use of eltrombopag after romiplostim in primary immune thrombocytopenia. British Journal of Haematology, 2015, 169, 111-116.	2,5	66
368	Treatment of Immune Thrombocytopenia in Adults: The Role of Thrombopoietin-Receptor Agonists. Seminars in Hematology, 2015, 52, 16-24.	3.4	31
369	Eltrombopag in Aplastic Anemia. Seminars in Hematology, 2015, 52, 31-37.	3.4	34
370	Immune Thrombocytopenia. Clinical and Applied Thrombosis/Hemostasis, 2015, 21, 397-404.	1.7	22
371	Catastrophic antiphospholipid syndrome (CAPS) precipitated by cardiac surgery: A case report and review of the literature. Case Reports in Internal Medicine, 2016, 3, 73.	0.0	0
372	Rate of bleeding-related episodes in adult patients with primary immune thrombocytopenia: a retrospective cohort study using a large administrative medical claims database in the US. Clinical Epidemiology, 2016, 8, 231.	3.0	24
373	Searching for a Light at the End of the Tunnel? Beyond Hypomethylating Agents in Myelodysplastic Syndromes. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e345-e352.	3.8	1
374	The Use of Thrombopoietin Receptor Agonists for Correction of Thrombocytopenia prior to Elective Procedures in Chronic Liver Diseases: Review of Current Evidence. International Journal of Hepatology, 2016, 2016, 1-9.	1.1	27
375	Eltrombopag for the treatment of aplastic anemia: current perspectives. Drug Design, Development and Therapy, 2016, Volume 10, 2833-2843.	4.3	20
376	Endometriosis and Ovarian Cancer: From Molecular Evidences to Clinical Implications. Journal of Endometriosis and Pelvic Pain Disorders, 2016, 8, 81-86.	0.5	5
377	Small Molecules. , 2016, , 87-110.		3
378	Efficacy and safety of eltrombopag in treatment-refractory primary immune thrombocytopenia. Blood Coagulation and Fibrinolysis, 2016, 27, 47-52.	1.0	12
379	Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study. Pediatric Blood and Cancer, 2016, 63, 1407-1413.	1.5	70
380	Successful use of eltrombopag in a child with refractory immune thrombocytopenia. Blood Coagulation and Fibrinolysis, 2016, 27, 825-827.	1.0	3

#	Article	IF	CITATIONS
381	Pathogenesis-oriented approaches for the management of corticosteroid-resistant or relapsedprimary immune thrombocytopenia. Open Medicine (Poland), 2016, 11, 97-100.	1.3	1
382	Erythropoietin and thrombopoietin mimetics: Natural alternatives to erythrocyte and platelet disorders. Critical Reviews in Oncology/Hematology, 2016, 108, 175-186.	4.4	9
383	Efficacy and safety of thrombopoietin receptor agonists in patients with primary immune thrombocytopenia: A systematic review and meta-analysis. Scientific Reports, 2016, 6, 39003.	3.3	48
384	Eltrombopag: liver toxicity, kidney injury or assay interference?. Pathology, 2016, 48, 754-756.	0.6	7
385	Sequential sampling: a novel method in farm animal welfare assessment. Animal, 2016, 10, 349-356.	3.3	10
386	Thrombopoietin receptor agonists: a new immune modulatory strategy in immune thrombocytopenia?. Seminars in Hematology, 2016, 53, S31-S34.	3.4	36
387	Eltrombopag: A Review in Paediatric Chronic Immune Thrombocytopenia. Drugs, 2016, 76, 869-878.	10.9	27
388	Thrombopoietin receptor agonists shift the balance of FcÎ ³ receptors toward inhibitory receptor IIb on monocytes in ITP. Blood, 2016, 128, 852-861.	1.4	62
389	Eltrombopag Use in Patients With Chronic Myelomonocytic Leukemia (CMML): A Cautionary Tale. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, S64-S66.	0.4	28
391	Eltrombopag (thrombopoietinâ€receptor agonist) and plasmapheresis as rescue therapy of acute postâ€renal transplant immune thrombocytopenia in a child with Schimke immunoâ€osseous dysplasia—case report. Pediatric Transplantation, 2016, 20, 1148-1151.	1.0	5
392	Immune thrombocytopenia: a comprehensive review from pathophysiology to promising treatment modalities. Expert Opinion on Orphan Drugs, 2016, 4, 1217-1227.	0.8	2
393	Immune-Mediated Thrombocytopenia. , 2016, , 209-220.		0
394	Advances in Diagnosis and Treatments for Immune Thrombocytopenia. Clinical Medicine Insights Blood Disorders, 2016, 9, CMBD.S39643.	0.3	38
395	Cost-Effectiveness of Eltrombopag versus Romiplostim for the Treatment of Chronic Immune Thrombocytopenia in England and Wales. Value in Health, 2016, 19, 614-622.	0.3	13
396	Gender and duration of disease differentiate responses to rituximab–dexamethasone therapy in adults with immune thrombocytopenia. American Journal of Hematology, 2016, 91, 907-911.	4.1	45
397	Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice. European Journal of Haematology, 2016, 97, 297-302.	2.2	34
398	A 2-Year, Longitudinal, Prospective Study of the Effects of Eltrombopag on Bone Marrow in Patients with Chronic Immune Thrombocytopenia. Acta Haematologica, 2017, 137, 66-72.	1.4	33
399	Beyond immune thrombocytopenia: the evolving role of thrombopoietin receptor agonists. Annals of Hematology, 2017, 96, 1421-1434.	1.8	33

#	ARTICLE Therapy induced iron deficiency in children treated with eltrombopag for immune thrombocytopenia.	IF 4 1	CITATIONS
401	American Journal of Hematology, 2017, 92, E88-E91. From chronic immune thrombocytopenia to severe aplastic anemia: recent insights into the evolution of eltrombopag. Therapeutic Advances in Hematology, 2017, 8, 159-174.	2.5	29
402	A practical guide to the use of eltrombopag in children with chronic immune thrombocytopenia. Pediatric Hematology and Oncology, 2017, 34, 73-89.	0.8	11
403	Safety, Pharmacokinetics and Pharmacodynamics of Hetrombopag Olamine, a Novel <scp>TPO</scp> â€R Agonist, in Healthy Individuals. Basic and Clinical Pharmacology and Toxicology, 2017, 121, 414-422.	2.5	21
404	Immune Thrombocytopenia: Where Are We Now?. , 2017, , 749-760.		0
405	Therapeutic Use of Thrombopoietin Receptor Agonists. , 2017, , 1417-1429.		0
406	Thrombopoetin receptor agonist therapy in thrombocytopenia: ITP and beyond. British Journal of Haematology, 2017, 177, 475-480.	2.5	9
407	Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. Blood, 2017, 130, 2527-2536.	1.4	228
408	TPO for ITP in pregnancy. Blood, 2017, 130, 1073-1074.	1.4	4
409	Eltrombopag: a powerful chelator of cellular or extracellular iron(III) alone or combined with a second chelator. Blood, 2017, 130, 1923-1933.	1.4	98
410	Thrombopoietin receptor agonist switch in adult primary immune thrombocytopenia patients: A retrospective collaborative survey involving 4 Spanish centres. European Journal of Haematology, 2017, 99, 372-377.	2.2	17
411	Diagnosis and Treatment of Aplastic Anemia. Current Treatment Options in Oncology, 2017, 18, 70.	3.0	79
412	Eltrombopag for secondary failure of platelet recovery postâ€allogeneic hematopoietic stem cell transplant in children. Pediatric Transplantation, 2017, 21, e13017.	1.0	17
413	Multicentre, randomised phase <scp>III</scp> study of the efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia. British Journal of Haematology, 2017, 176, 101-110.	2.5	55
414	Thrombocytopenia in chronic liver disease. Liver International, 2017, 37, 778-793.	3.9	183
415	Tolerability and Efficacy of Eltrombopag in Chronic Immune Thrombocytopenia: Meta-Analysis of Randomized Controlled Trials. Clinical and Applied Thrombosis/Hemostasis, 2017, 23, 928-937.	1.7	34
416	<scp>TPO</scp> â€ <scp>RA</scp> s in <scp>pITP</scp> : description of a case series and analysis of predictive factors for response. European Journal of Haematology, 2017, 98, 242-249.	2.2	14
417	Thrombocytopenia resistent to standard therapy in lupus patients – analysis of 3 cases and clinical statement. Annals of Agricultural and Environmental Medicine, 2017, 25, 229-233.	1.0	0

#	Article	IF	CITATIONS
418	Emerging New Therapies for Acquired Bone Marrow Failure Disorders. , 2017, , 153-167.		1
419	Efficacy of Repeated Lusutrombopag Administration for Thrombocytopenia in a Patient Scheduled for Invasive Hepatocellular Carcinoma Treatment. Internal Medicine, 2017, 56, 2887-2890.	0.7	14
421	Safety and efficacy of thrombopoeitin mimetics for refractory immune thrombocytopenia purpura in patients with systemic lupus erythematosus or antiphospholipid syndrome: a case series. Lupus, 2018, 27, 1723-1728.	1.6	14
422	Justicia adhatoda induces megakaryocyte differentiation through mitochondrial ROS generation. Phytomedicine, 2018, 43, 135-139.	5.3	12
423	Transitioning patients with immune thrombocytopenia to secondâ€line therapy: Challenges and best practices. American Journal of Hematology, 2018, 93, 816-823.	4.1	27
424	Guideline on immune thrombocytopenia in adults: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Project guidelines: Associação Médica Brasileira – 2018. Hematology, Transfusion and Cell Therapy, 2018, 40, 50-74.	0.2	18
425	Chinese guidelines for treatment of adult primary immune thrombocytopenia. International Journal of Hematology, 2018, 107, 615-623.	1.6	63
426	Long-term efficacy of partial splenic embolization for the treatment of steroid-resistant chronic immune thrombocytopenia. Annals of Hematology, 2018, 97, 655-662.	1.8	18
427	Atorvastatin enhances bone marrow endothelial cell function in corticosteroid-resistant immune thrombocytopenia patients. Blood, 2018, 131, 1219-1233.	1.4	40
428	Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placeboâ€controlled trials. American Journal of Hematology, 2018, 93, 921-930.	4.1	215
429	Eltrombopag for the Treatment of Refractory Pure RBC Aplasia after Major ABO Incompatible Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 1765-1770.	2.0	22
430	Modeling and Simulation Support Eltrombopag Dosing in Pediatric Patients With Immune Thrombocytopenia. Clinical Pharmacology and Therapeutics, 2018, 104, 1199-1207.	4.7	11
431	Antibody Therapy. , 2018, , .		0
432	Long-term outcomes of laparoscopic versus open splenectomy for immune thrombocytopenia. Surgery Today, 2018, 48, 180-185.	1.5	22
433	Neurological Complications of Chemotherapy. , 2018, , 275-310.		1
434	Diagnosis and treatment of MYH9-RD in an Australasian cohort with thrombocytopenia. Platelets, 2018, 29, 793-800.	2.3	15
435	A low birth weight infant with no malformations delivered by a primary immune thrombocytopenia patient treated with eltrombopag. International Journal of Hematology, 2018, 108, 109-111.	1.6	20
436	Thrombopoietin receptor agonists in patients with persistent or chronic immune thrombocytopenia. European Journal of Haematology, 2018, 100, 304-307.	2.2	1

#	Article	IF	CITATIONS
437	Chronic Thromboembolic Pulmonary Hypertension and Antiphospholipid Syndrome with Immune Thrombocytopenia: A Case Report. American Journal of Case Reports, 2018, 19, 1245-1248.	0.8	2
438	Efficacy and safety of thrombopoietin receptor agonists in children with chronic immune thrombocytopenia: a meta-analysis. Oncotarget, 2018, 9, 7112-7125.	1.8	10
439	Immune thrombocytopenia: improving quality of life and patient outcomes. Patient Related Outcome Measures, 2018, Volume 9, 369-384.	1.2	44
440	Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia. Cancer, 2018, 124, 4192-4201.	4.1	27
441	Eltrombopag-based combination treatment for immune thrombocytopenia. Therapeutic Advances in Hematology, 2018, 9, 309-317.	2.5	15
442	Avatrombopag. British Journal of Haematology, 2018, 183, 342-343.	2.5	5
443	Introductory Chapter: Thrombocytopenia. , 0, , .		0
444	Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. British Journal of Haematology, 2018, 183, 479-490.	2.5	131
445	Avatrombopag, an oral thrombopoietin receptor agonist: results of two doubleâ€blind, doseâ€rising, placeboâ€controlled Phase 1 studies. British Journal of Haematology, 2018, 183, 466-478.	2.5	22
446	Eltrombopag for use in children with immune thrombocytopenia. Blood Advances, 2018, 2, 454-461.	5.2	75
447	Pathophysiology of immune thrombocytopenia. Current Opinion in Hematology, 2018, 25, 373-381.	2.5	67
448	Pharmacological characterization of hetrombopag, a novel orally active human thrombopoietin receptor agonist. Journal of Cellular and Molecular Medicine, 2018, 22, 5367-5377.	3.6	26
449	Evidence-based management of immune thrombocytopenia: ASH guideline update. Hematology American Society of Hematology Education Program, 2018, 2018, 568-575.	2.5	60
450	Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia. Gastroenterology, 2018, 155, 705-718.	1.3	163
451	Acquired Aplastic Anemia. Pediatric Clinics of North America, 2018, 65, 597-606.	1.8	6
452	Evans Syndrome: Background, Clinical Presentation, Pathophysiology, and Management. , 2018, , 125-150.		1
453	Eltrombopag in immune thrombocytopenia: efficacy review and update on drug safety. Therapeutic Advances in Drug Safety, 2018, 9, 263-285.	2.4	40
454	Eltrombopag versus romiplostim in treatment of adult patients with immune thrombocytopenia: A systematic review incorporating an indirect-comparison meta-analysis. PLoS ONE, 2018, 13, e0198504.	2.5	23

#	Article	IF	CITATIONS
455	Drug-Induced Hematological Cytopenia in Kidney Transplantation and the Challenges It Poses for Kidney Transplant Physicians. Journal of Transplantation, 2018, 2018, 1-22.	0.5	25
456	Therapeutic Doses of Eltrombopag do not Inhibit Hepatic BCRP in Healthy Volunteers: Intravenous Ceftriaxone as a Model. Journal of Pharmacy and Pharmaceutical Sciences, 2018, 21, 236-246.	2.1	7
459	Chemical modulation of cell fates: in situ regeneration. Science China Life Sciences, 2018, 61, 1137-1150.	4.9	7
461	Thrombopoietin Receptor Agonists: Characteristics, Adverse Effects, and Indications. , 2018, , 261-276.		0
462	Thrombopoietin Receptor Agonists: Can These Be the Future Answer to the Deadly Thrombocytopenia in Dengue Fever?. Cureus, 2019, 11, e4361.	0.5	0
463	Eltrombopag in Immune Thrombocytopenia, Aplastic Anemia, and Myelodysplastic Syndrome: From Megakaryopoiesis to Immunomodulation. Drugs, 2019, 79, 1305-1319.	10.9	36
464	Current and emerging treatments for immune thrombocytopenia. Expert Review of Hematology, 2019, 12, 723-732.	2.2	13
465	Current Advance in Thrombopoietin Receptor Agonists in the Management of Thrombocytopenia Associated With Chronic Liver Disease: Focus on Avatrombopag. Plasmatology, 2019, 12, 1179545X1987510.	0.4	10
466	Mechanisms and therapeutic prospects of thrombopoietin receptor agonists. Seminars in Hematology, 2019, 56, 262-278.	3.4	25
467	Efficacy and safety of eltrombopag in the treatment of severe chronic immune thrombocytopenia in children of China: A single-center observational study. International Journal of Immunopathology and Pharmacology, 2019, 33, 205873841987212.	2.1	7
468	Eltrombopag is an effective and safe therapy for refractory thrombocytopenia after haploidentical hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2019, 54, 1310-1318.	2.4	38
469	Therapeutic options for adult patients with previously treated immune thrombocytopenia – a systematic review and network meta-analysis. Hematology, 2019, 24, 290-299.	1.5	11
470	Eltrombopag for post-transplant cytopenias due to poor graft function. Bone Marrow Transplantation, 2019, 54, 1346-1353.	2.4	43
471	Eltrombopag for Treating Thrombocytopenia after Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1320-1324.	2.0	39
472	Immunomodulation in Primary Immune Thrombocytopenia: A Possible Role of the Fc Fragment of Romiplostim?. Frontiers in Immunology, 2019, 10, 1196.	4.8	17
473	Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of the Spanish Group of Hematopoietic Stem Cell Transplant. Biology of Blood and Marrow Transplantation, 2019, 25, 1825-1831.	2.0	34
474	Thrombopoietin receptor agonists: ten years later. Haematologica, 2019, 104, 1112-1123.	3.5	219
475	Synthesis of 1â€Substituted Pyrazolines by Reaction of Donorâ€Acceptor Cyclopropanes with 1,5â€Diazabicyclo[3.1.0]hexanes. European Journal of Organic Chemistry, 2019, 20 <u>19, 5475-5485.</u>	2.4	19

#	Article	IF	CITATIONS
476	A novel sponge-derived protein thrombocorticin is a new agonist for thrombopoietin receptor. Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology, 2019, 221, 82-88.	2.6	14
477	A 29-year-old woman with persistent thrombocytopenia. Internal and Emergency Medicine, 2019, 14, 1317-1320.	2.0	1
478	Immune Thrombocytopenia (ITP). , 2019, , 707-724.		3
479	A case of immune thrombocytopenia associated with invasive thymoma successfully treated with eltrombopag. Blood Research, 2019, 54, 74-79.	1.3	1
480	Fostamatinib for the treatment of immune thrombocytopenia in adults. American Journal of Health-System Pharmacy, 2019, 76, 789-794.	1.0	11
481	Longâ€ŧerm fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program. American Journal of Hematology, 2019, 94, 546-553.	4.1	67
482	Multiple concomitant mechanisms contribute to low platelet count in patients with immune thrombocytopenia. Scientific Reports, 2019, 9, 2208.	3.3	30
483	Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: a phase 2 multicenter study. Blood, 2019, 134, 1708-1711.	1.4	16
484	American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Advances, 2019, 3, 3829-3866.	5.2	684
485	Thrombopoietin Receptor Agonist Use for Immune Thrombocytopaenia. Hamostaseologie, 2019, 39, 272-278.	1.9	9
486	Understanding how older age drives decisionâ€making and outcome in Immune Thrombocytopenia. A single centre study on 465 adult patients. British Journal of Haematology, 2019, 184, 424-430.	2.5	16
487	A phase <scp>II</scp> trial of eltrombopag for patients with chronic lymphocytic leukaemia (<scp>CLL</scp>) and thrombocytopenia. British Journal of Haematology, 2019, 185, 606-608.	2.5	8
488	Changes in healthâ€related quality of life with longâ€ŧerm eltrombopag treatment in adults with persistent/chronic immune thrombocytopenia: Findings from the EXTEND study. American Journal of Hematology, 2019, 94, 200-208.	4.1	22
489	Comparison of treatments for persistent/chronic immune thrombocytopenia: a systematic review and network meta-analysis. Platelets, 2019, 30, 946-956.	2.3	10
490	Chronic Immune Thrombocytopenia. , 2019, , 619-622.		0
491	Systematic literature review of treatments used for adult immune thrombocytopenia in the secting. American Journal of Hematology, 2019, 94, 118-132.	4.1	27
492	General Aspects of Thrombocytopenia, Platelet Transfusions, and Thrombopoietic Growth Factors. , 2019, , 108-126.		6
493	Immune Thrombocytopenia. , 2019, , 127-144.		3

#	Article	IF	CITATIONS
494	Effect of thrombopoietin receptor agonists on markers of coagulation and P-selectin in patients with immune thrombocytopenia. Platelets, 2019, 30, 206-212.	2.3	21
495	Trilineage Hematopoiesis Induced by Low-dose Eltrombopag in a Patient With Fanconi Anemia can be Used as a Bridge to Hematopoietic Stem Cell Transplant. Journal of Pediatric Hematology/Oncology, 2019, 41, 229-232.	0.6	2
496	Immune thrombocytopenia is associated with persistently deranged fibrosis-related seromarker profiles but low bone marrow fibrosis grades: A 2-year observational study on thrombopoietin receptor agonist treatment. Platelets, 2019, 30, 222-228.	2.3	1
497	Eltrombopag: Role in Cytopenias Following Hematopoietic Stem Cell Transplantation. Indian Journal of Hematology and Blood Transfusion, 2020, 36, 238-245.	0.6	6
498	Treatment efficacy for adult persistent immune thrombocytopenia: a systematic review and network metaâ€analysis. British Journal of Haematology, 2020, 188, 450-459.	2.5	26
499	Thrombocytopenia and thrombocytosis. , 2020, , 695-719.		1
500	Pyrazolone structural motif in medicinal chemistry: Retrospect and prospect. European Journal of Medicinal Chemistry, 2020, 186, 111893.	5.5	114
502	Tapering and discontinuation of thrombopoietin receptor agonists in immune thrombocytopenia: Real-world recommendations. Blood Reviews, 2020, 41, 100647.	5.7	20
503	Reference guide for management of adult immune thrombocytopenia in Japan: 2019 Revision. International Journal of Hematology, 2020, 111, 329-351.	1.6	38
504	Early combination treatment of immune thrombocytopenia: Is this the way?. American Journal of Hematology, 2020, 95, 1452-1453.	4.1	0
505	Summarising salient information on historical controls: A structured assessment of validity and comparability across studies. Clinical Trials, 2020, 17, 607-616.	1.6	18
506	Identification of Modulators of HIV-1 Proviral Transcription from a Library of FDA-Approved Pharmaceuticals. Viruses, 2020, 12, 1067.	3.3	4
507	Sirolimus versus cyclosporine for the treatment of pediatric chronic immune thrombocytopenia: A randomized blinded trial. International Immunopharmacology, 2020, 88, 106895.	3.8	13
508	Occurrence and Management of Thrombocytopenia in Metastatic Colorectal Cancer Patients Receiving Chemotherapy: Secondary Analysis of Data From Prospective Clinical Trials. Clinical Colorectal Cancer, 2021, 20, 170-176.	2.3	16
509	Investigation of the efficacy and safety of eltrombopag to correct thrombocytopenia in moderate to severe dengue patients - a phase II randomized controlled clinical trial. EClinicalMedicine, 2020, 29-30, 100624.	7.1	6
510	Evans' Syndrome: From Diagnosis to Treatment. Journal of Clinical Medicine, 2020, 9, 3851.	2.4	50
511	A Blueprint for Identifying Phenotypes and Drug Targets in Complex Disorders with Empirical Dynamics. Patterns, 2020, 1, 100138.	5.9	9
512	Firstâ€inâ€patient study of hetrombopag in patients with chronic idiopathic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2020, 18, 3053-3060.	3.8	13

		CITATION RE	PORT	
#	Article		IF	CITATIONS
513	Impact of iron overload on bone remodeling in thalassemia. Archives of Osteoporosis,	2020, 15, 143.	2.4	6
514	Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with print thrombocytopenia. Blood Advances, 2020, 4, 4136-4146.	mary immune	5.2	60
515	Efficacy and safety of eltrombopag in Chinese patients with chronic immune thromboo 2 results from a multicenter phase III study. Platelets, 2022, 33, 82-88.	:ytopenia: stage	2.3	17
516	Tacrolimus is effective in relapsed/refractory autoimmune cytopenias: results of a singl retrospective study. Hematology, 2020, 25, 478-483.	e-center	1.5	8
517	Effect of Food on the Pharmacokinetic and Pharmacodynamic Profiles of Hetrombopag Volunteers. Clinical Therapeutics, 2020, 42, 2280-2288.	g in Healthy	2.5	10
518	Rescue treatment with eltrombopag in refractory cytopenias after allogeneic stem cell transplantation. Therapeutic Advances in Hematology, 2020, 11, 204062072096191.		2.5	9
519	Treatment-free remission after thrombopoietin receptor agonist discontinuation in pat newly diagnosed immune thrombocytopenia: an observational retrospective analysis ir clinical practice. International Journal of Hematology, 2020, 112, 159-168.	ients with 1 real-world	1.6	20
520	Immune thrombocytopenia in adults: A singleâ€centre review of demographics, clinica treatment outcomes. European Journal of Haematology, 2020, 105, 344-351.	l features and	2.2	5
521	Effect of three or more treatments with lusutrombopag in patients with cirrhotic thror A retrospective singleâ€center study. Hepatology Research, 2020, 50, 1101-1105.	nbocytopenia:	3.4	5
522	A novel PrECOG (PrE0901) dose-escalation trial using eltrombopag: enhanced platelet consolidation therapy in acute myeloid leukemia. Leukemia and Lymphoma, 2020, 61,	recovery during 2191-2199.	1.3	4
523	Thrombopoietin receptor agonist is more effective than platelet transfusion for chronic with thrombocytopenia, shown by propensity score matching. Hepatology Research, 2 1062-1070.	c liver disease 020, 50,	3.4	8
524	Real-world evidence on clinical outcomes in immune thrombocytopenia treated with th receptor agonists. Journal of Comparative Effectiveness Research, 2020, 9, 447-457.	nrombopoietin	1.4	11
525	Eltrombopag treatment of a dog with idiopathic aplastic pancytopenia. Journal of Vete Medicine, 2020, 34, 890-892.	rinary Internal	1.6	3
526	Eltrombopag for thrombocytopenia following allogeneic hematopoietic stem cell trans children. Pediatric Blood and Cancer, 2020, 67, e28208.	plantation in	1.5	11
527	Effect of postdose fasting duration on hetrombopag olamine pharmacokinetics and pharmacodynamics in healthy volunteers. British Journal of Clinical Pharmacology, 202	0, 86, 1528-1536.	2.4	18
528	Fatigue, executive function and psychological effects in children with immune thrombo crossâ€sectional study. British Journal of Haematology, 2020, 189, 534-542.	ocytopenia: a	2.5	5
529	Safety and efficacy of eltrombopag plus pulsed dexamethasone as firstâ€line therapy f thrombocytopenia. British Journal of Haematology, 2020, 189, 369-378.	or immune	2.5	32
530	The Cost-effectiveness of Eltrombopag for the Treatment of Immune Thrombocytopen States. Clinical Therapeutics, 2020, 42, 860-872.e8.	ia in the United	2.5	6

#	Article	IF	CITATIONS
531	Novel ET mutations: stuck in the MPL with you. Blood, 2020, 135, 889-890.	1.4	0
532	The Thrombopoietin Receptor Agonist Lusutrombopag Is Effective for Patients with Chronic Liver Disease and Impaired Renal Function. Journal of Nippon Medical School, 2020, 87, 325-333.	0.9	4
533	Thrombopoietin receptor agonists for the treatment of primary immune thrombocytopenia: a meta-analysis and systematic review. Platelets, 2021, 32, 216-226.	2.3	25
535	Immune thrombocytopenia (ITP) World Impact Survey (iWISh): Patient and physician perceptions of diagnosis, signs and symptoms, and treatment. American Journal of Hematology, 2021, 96, 188-198.	4.1	55
536	Efficacy of romiplostim in treatment of thrombocytopenia in children with Wiskott–Aldrich syndrome. British Journal of Haematology, 2021, 192, 366-374.	2.5	10
537	Initial <i>inÂvivo</i> testing of TPO-receptor agonist eltrombopag in osteosarcoma patient-derived xenograft models by the pediatric preclinical testing consortium. Pediatric Hematology and Oncology, 2021, 38, 8-13.	0.8	6
538	Eltrombopag-Associated Acneiform Rash: A Case Report. American Journal of Therapeutics, 2021, 28, e245-e246.	0.9	1
539	Assessment of thrombotic risk during long-term treatment of immune thrombocytopenia with fostamatinib. Therapeutic Advances in Hematology, 2021, 12, 204062072110108.	2.5	26
540	Laparoscopic Splenectomy. , 2021, , 439-457.		0
541	Comparative Utilization and Efficacy of Thrombopoietin Receptor Agonists in Relapsed/Refractory Immune Thrombocytopenia. American Journal of Therapeutics, 2021, 28, e525-e530.	0.9	2
542	Current evidence and the emerging role of eltrombopag in severe aplastic anemia. Therapeutic Advances in Hematology, 2021, 12, 204062072199812.	2.5	20
543	Impaired Hematopoiesis after Allogeneic Hematopoietic Stem Cell Transplantation: Its Pathogenesis and Potential Treatments. Hemato, 2021, 2, 43-63.	0.6	3
544	A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia. Journal of Hematology and Oncology, 2021, 14, 37.	17.0	33
545	The incidence of thrombocytopenia in adult patients receiving chemotherapy for solid tumors or hematologic malignancies. European Journal of Haematology, 2021, 106, 662-672.	2.2	31
546	Eltrombopag Add-on Treatment in a Child With Fanconi Aplastic Anemia Awaiting Hematopoietic Stem Cell Transplantation. Journal of Pediatric Hematology/Oncology, 2021, Publish Ahead of Print, .	0.6	0
547	Eltrombopag Improves Erythroid Differentiation in a Human Induced Pluripotent Stem Cell Model of Diamond Blackfan Anemia. Cells, 2021, 10, 734.	4.1	11
548	Organocatalytic Amination of Pyrazolones with Azodicarboxylates: Scope and Limitations. European Journal of Organic Chemistry, 2021, 2021, 2362-2366.	2.4	7
549	The treatment of immune thrombocytopenia (ITP)—focus on thrombopoietin receptor agonists. Annals of Blood, 0, 6, 7-7.	0.4	10

		CITATION RE	PORT	
#	Article		IF	CITATIONS
550	Eltrombopag in children with severe aplastic anemia. Pediatric Blood and Cancer, 2021, 68,	e29066.	1.5	11
551	Acute kidney injury and nephrotic syndrome associated with eltrombopag therapy in chronic idiopathic thrombocytopenic purpura. BMJ Case Reports, 2021, 14, e241462.	c	0.5	4
553	Thrombosis in immune thrombocytopenia — current status and future perspectives. Britisl Haematology, 2021, 194, 822-834.	h Journal of	2.5	31
554	Safety and Efficacy of Eltrombopag in Children and Adults with Immune Thrombocytopenia: Systematic Review and Meta-Analysis. Cardiovascular and Hematological Agents in Medicina Chemistry, 2021, 19, 83-92.	A al	1.0	3
555	Immune Thrombocytopenia: Recent Advances in Pathogenesis and Treatments. HemaSphere	e, 2021, 5, e574.	2.7	45
556	Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for Pharmacists. D 81, 1285-1305.)rugs, 2021,	10.9	35
557	Effect of Cytokine Gene Polymorphisms on Eltrombopag Reactivity in Japanese Patients with Thrombocytopenia. Journal of Blood Medicine, 2021, Volume 12, 421-429.	ו Immune	1.7	1
558	Efficacy and cost analysis of eltrombopag in thrombocytopenia and poor graft function pos allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2021, 56, 247	t 1-2476.	2.4	5
559	Relative Dose Intensity of Chemotherapy and Survival in Patients with Advanced Stage Solid Cancer: A Systematic Review and <scp>Meta-Analysis</scp> . Oncologist, 2021, 26, e1609-6	l Tumor ≥1618.	3.7	55
560	Treatment of immune thrombocytopenia with eltrombopag in patients who had and who ha received prior rituximab: <i>postâ€hoc</i> analysis of the EXTEND study. British Journal of H 2022, 196, 448-452.	id not Iaematology,	2.5	0
561	Use of eltrombopag and granulocyteâ€colony stimulatingâ€factor in treatment of lomustin a dog. Veterinary Record Case Reports, 0, , e174.	e overdose in	0.2	1
562	Corticosteroid overuse in adults with immune thrombocytopenia: Cause for concern. Resear Practice in Thrombosis and Haemostasis, 2021, 5, e12592.	rch and	2.3	15
563	Management of the Older Patient with Myelodysplastic Syndrome. Drugs and Aging, 2021,	38, 751-767.	2.7	9
564	SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP. Blood, 2022, 13	9, 1564-1574.	1.4	55
565	A multicentre doubleâ€blind, doubleâ€dummy, randomised study of recombinant human th <i>versus</i> eltrombopag in the treatment of immune thrombocytopenia in Chinese adult British Journal of Haematology, 2021, 195, 781-789.	rombopoietin patients.	2.5	14
566	Eltrombopag treatment of patients with secondary immune thrombocytopenia: retrospectiv analysis. Annals of Hematology, 2021, , 1.	ve EHR	1.8	2
567	Eltrombopag Effectiveness and Tolerability in Chronic Immune Thrombocytopenia: A Meta-A Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962110055.	nalysis.	1.7	3
568	The efficacy and safety of romiplostim in the treatment of thrombocytopenia in pediatric pa Wiskott–Aldrich syndrome: the results of a retrospective study. Pediatric Hematology/On Immunopathology, 2021, 19, 39-49.	tients with cology and	0.3	0

ARTICLE IF CITATIONS # Thrombocytopenia and Platelet Transfusions in Patients with Cancer. Cancer Treatment and Research, 570 0.5 7 2010, 157, 251-265. Eltrombopag. Cancer Treatment and Research, 2010, 157, 289-303. 571 572 On Stopping a Randomized Clinical Trial for Futility., 2012, , 109-137. 30 Tuning MPL signaling to influence hematopoietic stem cell differentiation and inhibit essential thrombocythemia progenitors. Proceedings of the National Academy of Sciences of the United States 24 of America, 2021, 118, Drug-induced thrombocytopenia secondary to natalizumab treatment. BMJ Case Reports, 2014, 2014, 576 0.5 13 bcr2013203313-bcr2013203313. SLE Thrombocytopenia: From Peripheral Platelet Destruction to Central Hemopoietic Defect. Open 577 0.3 Hematology Journal, 2008, 2, 111-118. Use of romiplostim for newly diagnosed immune thrombocytopenia in children. Pediatric 578 0.3 2 Hematology/Oncology and Immunopathology, 2020, 19, 18-26. Lupus thrombocytopenia: pathogenesis and therapeutic implications. Mediterranean Journal of 579 0.8 Rheumatology, 2017, 28, 20-26. Romiplostim for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a single 580 2.8 27 technology appraisal. Health Technology Assessment, 2009, 13, 63-8. Eltrombopag monotherapy can improve hematopoiesis in patients with low to intermediate risk-1 3.5 myelodysplastic syndrome. Haematologica, 2020, 105, 2785-2794. Management of thrombocytopenia due to liver cirrhosis: A review. World Journal of 582 104 3.3 Gastroenterology, 2014, 20, 2595. Long-Term Follow-Up of Adult Patients with Idiopathic Thrombocytopenic Purpura after Splenectomy. 0.0 Macedonian Journal of Medical Sciences, 2011, 4, 285-289. Resistant Thrombocytopenia in an HIV and Hepatitis C Patient: Treatment Response with Novel Agent 587 1.4 1 Eltrombopag. Clinics and Practice, 2011, 1, 7-8. Pathobiology and Treatment of Hepatitis Virus-Related Thrombocytopenia. Mediterranean Journal of 588 1.3 Hematology and Infectious Diseases, 2009, 1, e2009023. Cerebral venous thrombosis in refractory idiopathic thrombocytopenia treated with eltrombopag. 589 0.5 4 Annals of Indian Academy of Neurology, 2016, 19, 532. Idiopathic thrombocytopenic purpura. Contemporary Clinical Dentistry, 2014, 5, 410. Role of hematopoietic growth factors as adjuncts in the treatment of chronic hepatitis C patients. 591 1.1 11 Saudi Journal of Gastroenterology, 2008, 14, 151. Morbilliform eruption related to eltrombopag: emerging data on the cutaneous toxicity of thrombopoietin receptor agonists. Dermatology Online Journal, 2016, 22, .

	CITAI	ION REPORT	
#	Article	IF	CITATIONS
593	Use of eltrombopag in thrombocytopenia of liver disease. World Journal of Pharmacology, 2014, 3, 186.	2.3	1
594	Chronic hepatitis C-associated thrombocytopenia: aetiology and management. Tropical Gastroenterology: Official Journal of the Digestive Diseases Foundation, 2013, 34, 58-67.	0.0	13
595	Thrombopoietin receptor agonists for the treatment of severe persistent and chronic immune trombocytopenia in children: clinical data of Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology. Pediatric Hematology/Oncology and Immunopathology, 2021, 20, 12-25.	0.3	2
596	Targeted therapies for immune thrombocytopenic purpura: a meta-analysis of randomized controlled trials. Annals of Hematology, 2021, 100, 2879-2887.	1.8	3
597	Haematological Abnormalities in Cancer Patients. , 2009, , 783-811.		0
598	Disorders of Hemostasis. , 2010, , 1578-1589.		0
599	USE OF HEMATOPOIETIC GROWTH FACTOR IN THE MANAGEMENT OF HEMATOLOGICAL SIDE EFFECTS ASSOCIATED TO ANTIVIRAL TREATMENT FOR HCV HEPATITIS. Mediterranean Journal of Hematology and Infectious Diseases, 2010, 2, e2010003.	1.3	4
601	Bleeding Diathesis. , 2010, , 445-469.		0
602	Thrombocytopenia and Bleeding Disorders. , 2011, , 717-738.e5.		2
604	Eltrombopag for the treatment of chronic idiopathic (immune) thrombocytopenic purpura (ITP). Health Technology Assessment, 2011, 15, 23-32.	2.8	5
607	Hematologic Manifestations of SLE. , 2012, , 127-139.		3
608	Eltrombopag Thrombopoietin Receptor Agonist for Treatment of Immune Thrombocytopenia: Current and Future Considerations. Clinical Medicine Reviews in Vascular Health, 0, 4, 9-18.	3.0	0
609	Maintenance Therapy with Rituximab in Adult Patients with Immune Thrombocytopenia. Macedonian Journal of Medical Sciences, 2013, 6, .	0.0	1
610	Demographic and clinical analysis on hospitalized patients with thrombocytopenia. Journal of Applied Hematology, 2014, 5, 58.	0.3	0
611	Disorders of Blood Cell Production in Clinical Oncology. , 2014, , 532-541.e10.		2
613	Hematopoietic Growth Factors. Pediatric Oncology, 2015, , 247-260.	0.5	0
614	Risk of Thromboembolism in Patients with Immune Thrombocytopenia. Journal of Hematology & Thromboembolic Diseases, 2015, 03, .	0.1	1
615	Eltrombopag Use in Thrombocytopenia for Endoscopic Submucosal Dissection of a Gastric Carcinoid. ACG Case Reports Journal, 2015, 2, 24-26.	0.4	1

#	Article	IF	CITATIONS
616	Advanced Approaches to Diagnose and Treat the Chronic Autoimmune Disorders. Advances in Medical Diagnosis, Treatment, and Care, 2016, , 70-98.	0.1	0
617	Splenic artery embolization as a bridge to splenectomy in severe transfusion-refractory thrombocytopenia secondary to myelodysplastic syndrome. International Journal of Hematology & Therapy, 2016, 2, 1-5.	0.1	0
618	Advanced Approaches to Diagnose and Treat the Chronic Autoimmune Disorders. , 2017, , 1741-1770.		0
619	Pharmacoeconomic Analysis of the Use of Thrombopoietin Receptors Agonists in Idiopathic Thrombocytopenic Purpura Therapy. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2017, 10, 435-442.	0.4	0
620	Diagnosis and treatment of immune thrombocytopenia. Vnitrni Lekarstvi, 2018, 64, 526-529.	0.2	3
621	Management of adult immune thrombocytopenia: Recommendations by an expert Saudi panel. Journal of Applied Hematology, 2019, 10, 77.	0.3	0
622	Thrombocytopenia Post-transplantation: A Clinical Challenge in Need of a Therapy. , 2019, 16, .		0
623	Successful Use of Eltrombopag in a Pediatric Patient With Human Immunodeficiency Virus (HIV)–Associated Thrombocytopenia. Journal of Pediatric Pharmacology and Therapeutics, 2019, 24, 242-246.	0.5	0
624	INTERNISTISCHE INTENSIVMEDIZIN. , 2020, , K-1-K9-4.		0
625	Romiplostim and Eltrombopag in Immune Thrombocytopenia as a Second-Line Treatment. Cureus, 2020, 12, e9920.	0.5	8
626	Impact of targetâ€mediated drug disposition on hetrombopag pharmacokinetics and pharmacodynamics in Chinese healthy subjects and patients with chronic idiopathic thrombocytopenic purpura. British Journal of Clinical Pharmacology, 2021, , .	2.4	1
627	Immune thrombocytopenia. Expert Review of Hematology, 2021, 14, 1013-1025.	2.2	12
628	Thrombosis with Thrombocytopenia - A Vascular Paradox. Journal of Evidence Based Medicine and Healthcare, 2020, 7, 3110-3116.	0.0	0
629	The Use of High Dose Eltrombopag in the Management of Sepsis-Associated Thrombocytopenia in Critically III Patients. The Journal of Critical Care Medicine, 2019, 5, 123-129.	0.7	3
631	Cure of immune thrombocytopenic purpura: A homeopathic approach. GSC Biological and Pharmaceutical Sciences, 2020, 10, 085-088.	0.3	1
632	OUTCOMES OF ELTROMBOPAG TREATMENT AND DEVELOPMENT OF IRON DEFICIENCY IN CHILDREN WITH IMMUNE THROMBOCYTOPENIA IN TURKEY. Turkish Journal of Haematology, 2020, 37, 139-144.	0.5	6
634	Eltrombopag for the treatment of chronic idiopathic (immune) thrombocytopenic purpura (ITP). Health Technology Assessment, 2011, 15, 23-32.	2.8	5
637	Treatment of immune thrombocytopenic purpura: focus on eltrombopag. Biologics: Targets and Therapy, 2009, 3, 151-7.	3.2	9

#	Article	IF	CITATIONS
638	New advances in the treatment of adult chronic immune thrombocytopenic purpura: role of thrombopoietin receptor-stimulating agents. Biologics: Targets and Therapy, 2009, 3, 499-513.	3.2	5
639	Immune Thrombocytopenic Purpura in Children and Adults: A Comparative Retrospective Study in IRAN. International Journal of Hematology-Oncology and Stem Cell Research, 2014, 8, 30-6.	0.3	4
640	Childhood immune thrombocytopenia: Clinical presentation and management. Sudanese Journal of Paediatrics, 2012, 12, 27-39.	0.6	3
641	Clinical Practice Updates in the Management Of Immune Thrombocytopenia. P and T, 2017, 42, 756-763.	0.9	16
643	Real-world experience of eltrombopag in immune thrombocytopenia. American Journal of Blood Research, 2020, 10, 240-251.	0.6	13
644	Eltrombopag for refractory vaccine-induced immune thrombotic thrombocytopenia. Journal of Thrombosis and Thrombolysis, 2022, 53, 954-958.	2.1	4
645	Physiological and pharmacological modulation of BAX. Trends in Pharmacological Sciences, 2022, 43, 206-220.	8.7	82
646	Coordination compounds of pyrazoloneâ€based ligand: Design, characterization, biological evaluation, antitumor efficiency, and DNA binding evaluation supported by in silico studies. Applied Organometallic Chemistry, 2022, 36, e6508.	3.5	30
647	Efficacy and safety of thrombopoietin receptor agonists in the treatment of thrombocytopenia after hematopoietic stem cell transplantation: a meta-analysis and systematic review. Expert Review of Hematology, 2021, 14, 1041-1048.	2.2	7
648	Safety and efficacy of hetrombopag in patients with chronic immune thrombocytopenia: a single-arm, open-label, multi-center phase 1 study. Annals of Translational Medicine, 2022, 10, 30-30.	1.7	4
649	Risk of thrombosis with thrombopoietin receptor agonists for ITP patients: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2022, 171, 103581.	4.4	23
650	Eltrombopag inhibits TET dioxygenase to contribute to hematopoietic stem cell expansion in aplastic anemia. Journal of Clinical Investigation, 2022, 132, .	8.2	15
651	Immunosuppressive therapy in severe aplastic anemia. Seminars in Hematology, 2022, 59, 21-29.	3.4	9
652	Catastrophic anti-phospholipid syndrome with Libman-Sacks endocarditis following eltrombopag therapy for immune thrombocytopenic purpura: A case report. Lupus, 2021, 30, 2304-2309.	1.6	4
653	Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study. British Journal of Haematology, 2022, 197, 359-366.	2.5	31
654	Use of Eltrombopag for the First Trimester Pregnancy Complicated with Refractory Idiopathic Thrombocytopenic Purpura: A Case Report and Literature Review. Cureus, 2022, 14, e22505.	0.5	1
655	Eltrombopag for Treatment of Thrombocytopenia After Hematopoietic Stem Cell Transplantation. Turkish Journal of Haematology, 2022, , .	0.5	1
656	Longâ€term eltrombopag for bone marrow failure depletes iron. American Journal of Hematology, 2022, 97, 791-801.	4.1	8

ARTICLE IF CITATIONS Management of immune thrombocytopenia: 2022 update of Korean experts recommendations. Blood 657 1.3 10 Research, 2022, 57, 20-28. Thrombocytopenia and Therapeutic Strategies after Allogeneic Hematopoietic Stem Cell 2.4 Transplantation. Journal of Clinical Medicine, 2022, 11, 1364. 1,3â€diarylpyrazolones as potential anticancer agents for nonâ€small cell lung cancer: Synthesis and 659 3.24 antiproliferative activity evaluation. Chemical Biology and Drug Design, 2022, 99, 620-633. Real-World Use of Fostamatinib in Patients with Immune Thrombocytopenia and Thrombotic Risk. Acta 660 1.4 Haematologica, 2022, 145, 221-228. Myelodysplastic syndromes (MDS)., 0, , 103-115. 661 0 Treatment of immune thrombocytopenic purpura: focus on eltrombopag. Biologics: Targets and 3.2 Therapy, 2009, 3, 151. THE CLINICAL PROFILE AND OUTCOME OF TREATMENT OF IMMUNE THROMBOCYTOPENIA PATIENTS IN 664 0 IMPHAL., 2022, , 135-136. Recent advances in treatments of adult immune thrombocytopenia. Blood Research, 2022, 57, S112-S119. 1.3 665 Unusual complications in the management of <scp>chronic lymphocytic leukemia</scp>. American 666 4.1 1 Journal of Hematology, 2022, , . Investigational drugs for immune thrombocytopenia. Expert Opinion on Investigational Drugs, 2022, 4.1 1-13. Safety, tolerance, pharmacokinetic and pharmacodynamic properties of thrombopoietin mimetic peptide for injection in Chinese healthy volunteers: a randomized, placebo-controlled, double-blind 668 0 2.3study. Platelets, 2022, , 1-7. Oral eltrombopag versus subcutaneous recombinant human thrombopoietin for promoting platelet engraftment after allogeneic stem cell transplantation: A prospective, nonâ€inferiority, randomized controlled trial. Hematological Oncology, 2022, 40, 777-786. 1.7 Does eltrombopag lead to thrombotic events? A pharmacovigilance study of the <scp>FDA < scp>adverse event reporting system. Journal of Clinical Pharmacy and Therapeutics, 670 1.5 2 2022, 47, 1556-1562. Generation of a thrombopoietinâ€deficient thrombocytopenia model in zebrafish. Journal of 671 3.8 Thrombosis and Haemostasis, 2022, 20, 1900-1909. Severe secondary immune thrombocytopenia in a patient with chronic lymphocytic leukemia. 672 0 0.1 Onkologie (Czech Republic), 2022, 16, 151-154. Clinical Epidemiology, Treatment Outcome and Mortality Rate of Newly Diagnosed Immune Thrombocytopenia in Adult Multicentre Study in Malaysia. Journal of Blood Medicine, 0, Volume 13, 337-349. Diagnosis of immune thrombocytopenia, including secondary forms, and selection of second-line 674 3.5 4 treatment. Haematologica, 2022, 107, 2018-2036. Perioperative Management Using Thrombopoietin Receptor Agonists for a Patient with Breast Cancer Associated with ITPã€"A Case Reportâ€". Nihon Rinsho Geka Ğakkai Zasshi (Journal of Japan Surgical) Tj ETQq1 1 00784314 rgBT /Ove

#	Article	IF	CITATIONS
676	Avatrombopag for the Treatment of Immune Thrombocytopenia and Periprocedural Thrombocytopenia Associated With Chronic Liver Disease. Journal of Pharmacy Practice, 2024, 37, 184-189.	1.0	1
677	Treatment of congenital thrombocytopenia and decreased collagen reactivity in G6b-B–deficient mice. Blood Advances, 2023, 7, 46-59.	5.2	1
678	Combination of two target agonists of the thrombopoietin and thrombopoietin receptor in the treatment of elderly patients with refractory immune thrombocytopenia. , 2023, 1, 154-156.		0
679	Eltrombopag-Induced Myelofibrosis in Patients with Adult Immune Thrombocytopenia: Scoping Review. European Medical Journal Hematology, 0, , 69-79.	0.0	0
680	Fostamatinib for the treatment of Japanese patients with primary immune thrombocytopenia: A phase 3, placeboâ€controlled, doubleâ€blind, parallelâ€group study. British Journal of Haematology, 2023, 200, 802-811.	2.5	3
681	Powerful Potential of Polyfluoroalkyl-Containing 4-Arylhydrazinylidenepyrazol-3-ones for Pharmaceuticals. Molecules, 2023, 28, 59.	3.8	4
682	Recombinant human thrombopoietin (rhTPO) of different dosing regimens for refractory/relapsed primary immune thrombocytopenia: a multicenter, randomized controlled trial and pharmacokinetics study. Platelets, 2023, 34, .	2.3	4
683	Survival in adult patients with chronic primary and secondary immune thrombocytopenia: A populationâ€based study. Transfusion, 2023, 63, 415-426.	1.6	3
684	Risk of Thromboembolism With Eltrombopag: A Case Report of Deep Vein Thrombosis and Bilateral Pulmonary Embolism. Cureus, 2023, , .	0.5	1
685	Synthesis of phenazone based carboxamide under thiourea reaction conditions. Molecular and crystal structure, Hirshfeld surface analysis and intermolecular interaction energies. Journal of Molecular Structure, 2023, 1278, 134948.	3.6	3
686	Platelet kinetics in patients with chronic immune thrombocytopaenia treated with thrombopoietin receptor agonists. European Journal of Haematology, 2023, 110, 548-553.	2.2	1
687	Efficacy and safety of biosimilar romiplostim in Indian patients with chronic immune thrombocytopenia: A multicentric retrospective study. Indian Journal of Pathology and Microbiology, 2023, 66, 96.	0.2	1
688	Cell Death Markers in Children with Immune Thrombocytopenic Purpura: A Preliminary Study. Indian Journal of Hematology and Blood Transfusion, 0, , .	0.6	0
689	DABCO-Catalyzed Mono-/Diallylation of N-Unsubstituted Isatin N,N′-Cyclic Azomethine Imine 1,3-Dipoles with Morita-Baylis-Hillman Carbonates. Molecules, 2023, 28, 3002.	3.8	0
690	Efficacy and safety of thrombopoietin receptor agonists in children and adults with persistent and chronic immune thrombocytopenia: a meta-analysis. Expert Opinion on Pharmacotherapy, 2023, 24, 763-774.	1.8	2
691	Safety Profile of Eltrombopag in Different Age Groups: An Analysis of <scp>Realâ€World</scp> Pharmacovigilance and Randomized Clinical Trials. Clinical Pharmacology and Therapeutics, 2023, 114, 201-210.	4.7	0
692	Knowledge mapping of immune thrombocytopenia: a bibliometric study. Frontiers in Immunology, 0, 14,	4.8	2
693	Stereoselective and efficient chemical transformation of aldehydes and two molecules of pyrazolin-5-one into bis(spiropyrazolone)cyclopropanes under a column chromatography-free protocol at room temperature. Monatshefte FA¼r Chemie, 2023, 154, 625-633.	1.8	0

#	Article	IF	CITATIONS
694	A successful management of refractory immune thrombocytopenic purpura with Eltrombopag during pregnancy complicated with superimposed preeclampsia. Oxford Medical Case Reports, 2023, 2023, .	0.4	0
695	Eltrombopag for Adults and Children with Immune-Refractory Thrombocytopenic Purpura: A Systematic Review. Journal of Clinical Medicine, 2023, 12, 3872.	2.4	0
696	Avatrombopag, a promising novel thrombopoietin receptor agonist for refractory/relapsed/intolerant non-severe aplastic anemia: a phase 2 single-arm clinical trial. Annals of Medicine, 2023, 55, .	3.8	2
697	Risk of thrombotic events in immune thrombocytopenia patients treated with thrombopoietic agents: a systematic review and meta-analysis. Thrombosis Journal, 2023, 21, .	2.1	2
698	Cost-Effectiveness of Thrombopoietin Mimetics in Patients with Thrombocytopenia: A Systematic Review. Pharmacoeconomics, 2023, 41, 869-911.	3.3	0
699	Safety of non‑peptide thrombopoietin receptor agonists in patients with immune thrombocytopenia: A systematic review and meta‑analysis of short‑term double‑blind randomized clinical trials. Experimental and Therapeutic Medicine, 2023, 26, .	1.8	1
700	Eltrombopag in Lower-Risk Myelodysplastic Syndrome: Revival of Its Use in Thrombocytopenia. Journal of Clinical Oncology, 0, , .	1.6	0
701	Children with Chronic Immune Thrombocytopenia Exhibit High Expression of Human Endogenous Retroviruses TRIM28 and SETDB1. Genes, 2023, 14, 1569.	2.4	0
702	PEGylated thrombopoietin mimetic, JNJ‑26366821 a novel prophylactic radiation countermeasure for acute radiation injury. Scientific Reports, 2023, 13, .	3.3	1
703	Comparison of eltrombopag and avatrombopag in the treatment of refractory/relapsed aplastic anemia: a single-center retrospective study in China. Therapeutic Advances in Hematology, 2023, 14, .	2.5	1
704	Alternative treatment modality for severe aplastic anemia in a resource-limited setting: a single-institution prospective cohort study from Upper Egypt. Annals of Hematology, 2023, 102, 2997-3006.	1.8	0
705	Splenic Artery Embolization in a Patient With Intracranial Hemorrhage Due to Refractory Persistent Immune Thrombocytopenia. Journal of Pediatric Hematology/Oncology, 0, , .	0.6	0
706	Privileged scaffolds in anti-diabetic drug discovery. , 2023, , 357-375.		0
707	The efficacy and safety of eltrombopag in treating TKI-induced thrombocytopenia in patients with chronic myeloid leukemia. Hematology, 2023, 28, .	1.5	1
708	Rituximab Treatment for Severe Chronic Immune Thrombocytopenia in Children: A Report of 2 Cases and Literature Review. Advances in Clinical Medicine, 2023, 13, 15523-15529.	0.0	0
709	Hetrombopag plus recombinant human thrombopoietin for chemotherapy-induced thrombocytopenia in patients with solid tumors. Research and Practice in Thrombosis and Haemostasis, 2023, 7, 102231.	2.3	1
710	A Critical Analysis of the FDA's Omics-Driven Pharmacodynamic Biomarkers to Establish Biosimilarity. Pharmaceuticals, 2023, 16, 1556.	3.8	0
711	Severe Thrombocytopenia Due to Bone Marrow Failure in Children With Dyskeratosis Congenita Does Not Respond to Eltrombopag Treatment: Case Series. Journal of Pediatric Hematology/Oncology, 0, , .	0.6	0

CI	ΓΔΤΙ	ON	REDORT
	IAH		NEFORT

#	Article	IF	CITATIONS
712	How I treat thrombocytopenia in pregnancy. Blood, 2024, 143, 747-756.	1.4	0
713	The highs and lows of cyclic thrombocytopenia. British Journal of Haematology, 2024, 204, 56-67.	2.5	0
714	Thrombopoietin-receptor agonists for adult patients with immune thrombocytopenia: a narrative review and an approach for managing patients fasting intermittently. Frontiers in Cardiovascular Medicine, 0, 10, .	2.4	0
715	Thrombopoietin receptor agonists use and risk of thrombotic events in patients with immune thrombocytopenic purpura: A systematic review and meta‑analysis of randomized controlled trials. Biomedical Reports, 2024, 20, .	2.0	0
716	Translating mechanisms into therapeutic strategies for immune thrombocytopenia (ITP): Lessons from clinical trials. Thrombosis Research, 2024, 235, 125-147.	1.7	0
717	An iron rheostat controls hematopoietic stem cell fate. Cell Stem Cell, 2024, 31, 378-397.e12.	11.1	0
718	Realâ€world use of thrombopoietin receptor agonists for the management of immune thrombocytopenia in adult patients in the United Kingdom: Results from the <scp>TRAIT</scp> study. British Journal of Haematology, 0, , .	2.5	0